

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 23, 2003, 19:31:40 ; Search time 129 seconds
(without alignments)
5173.090 Million cell updates/sec

Title: PCT-US02-16639-1

Perfect score: 2176

Sequence: 1 attgtgtcaggttgaggc.....taggtgcaggttgcaaaa 2176

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents.NA.*

- 1: /cgn2_6/ptodata/1/ina/5A.COMB.seq.*
- 2: /cgn2_6/ptodata/1/ina/5B.COMB.seq.*
- 3: /cgn2_6/ptodata/1/ina/5A.COMB.seq.*
- 4: /cgn2_6/ptodata/1/ina/5B.COMB.seq.*
- 5: /cgn2_6/ptodata/1/ina/PCTUS.COMB.seq.*
- 6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
C 1	47.8	2.2	7218	1	US-08-232-463-14	Sequence 14, Appl
2	37.8	1.7	548	3	US-08-828-741B-1	Sequence 1, Appl
3	37.8	1.7	548	4	US-09-160-567-1	Sequence 1, Appl
C 4	35.4	1.6	1690	1	US-08-276-452A-24	Sequence 24, Appl
C 5	35.4	1.6	1690	2	US-08-798-744-24	Sequence 24, Appl
6	34.8	1.6	993	4	US-09-134-001C-745	Sequence 745, App
7	32.8	1.5	499	4	US-09-328-111-97	Sequence 97, Appl
8	32.6	1.5	964	3	US-08-755-587-23	Sequence 23, Appl
9	32.6	1.5	1041	3	US-08-755-587-22	Sequence 22, Appl
10	32.6	1.5	1050	3	US-08-755-587-21	Sequence 21, Appl
C 11	32.6	1.5	1432	5	PCT-US94-12912-4	Sequence 4, Appl
12	32.6	1.5	4770	4	US-09-000-094-45	Sequence 45, Appl
13	32.6	1.5	8010	4	US-09-521-526-2	Sequence 2, Appl
14	32.6	1.5	8010	5	PCT-US95-1189-2	Sequence 2, Appl
C 15	32.4	1.5	4550	4	US-09-462-136-1	Sequence 1, Appl
C 16	32.2	1.5	4253	3	US-08-577-483-7	Sequence 7, Appl
C 17	32.2	1.5	4254	2	US-08-443-639-7	Sequence 7, Appl
18	32	1.5	1031	3	US-08-828-741B-5	Sequence 5, Appl
19	32	1.5	1031	4	US-09-160-567-5	Sequence 5, Appl
20	32	1.5	1490	3	US-08-828-741B-3	Sequence 3, Appl
21	32	1.5	1490	4	US-09-160-567-3	Sequence 3, Appl
22	32	1.5	1939	4	US-08-961-527-310	Sequence 310, App
23	31.8	1.5	4233	4	US-09-056-103-27	Sequence 27, Appl
24	31.6	1.5	84495	4	US-09-797-906-3	Sequence 3, Appl
25	31.4	1.4	2277	1	US-08-676-967-2	Sequence 2, Appl
26	31.4	1.4	2277	1	US-08-676-974-2	Sequence 2, Appl
27	31.4	1.4	2277	2	US-09-098-487-2	Sequence 2, Appl

28	31.4	1.4	6393	4	US-09-323-872A-8	Sequence 8, Appl
29	31.2	1.4	155	1	US-07-626-618A-12	Sequence 12, Appl
30	31.2	1.4	155	1	US-08-333-977-12	Sequence 12, Appl
31	31.2	1.4	539	3	US-08-828-741B-12	Sequence 12, Appl
32	31.2	1.4	539	4	US-09-160-567-12	Sequence 12, Appl
33	31.2	1.4	563	1	US-07-928-611-8	Sequence 8, Appl
34	31.2	1.4	563	2	US-08-487-811A-8	Sequence 8, Appl
35	31.2	1.4	563	4	US-09-060-694-8	Sequence 8, Appl
36	31.2	1.4	563	4	US-09-378-074-8	Sequence 8, Appl
37	31.2	1.4	563	5	PCT-US93-07370-8	Sequence 8, Appl
38	31.2	1.4	599	3	US-08-828-741B-7	Sequence 7, Appl
39	31.2	1.4	599	4	US-09-160-567-7	Sequence 7, Appl
40	31.2	1.4	659	1	US-07-928-611-10	Sequence 10, Appl
41	31.2	1.4	659	2	US-08-487-811A-10	Sequence 10, Appl
42	31.2	1.4	659	4	US-09-060-694-10	Sequence 10, Appl
43	31.2	1.4	659	4	US-09-378-074-10	Sequence 10, Appl
44	31.2	1.4	659	5	PCT-US93-07370-10	Sequence 10, Appl
45	31.2	1.4	803	1	US-07-928-611-12	Sequence 12, Appl

ALIGNMENTS

RESULT 1
US-08-232-463-14/c
; Sequence 14, Application US/08232463
; Patent No. 5670367
; GENERAL INFORMATION:
; APPLICANT: DORNER, F.
; APPLICANT: SCHEIFLINGER, F.
; APPLICANT: FALKNER, F. G.
; TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 1800 Diagonal Road, Suite 500
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,463
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/935,313
; FILING DATE:
; APPLICATION NUMBER: EP 91 114 300.6
; FILING DATE: 28-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 30472/114 INMU
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)836-9300
; TELEFAX: (703)883-4109
; TELEX: 899149
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7218 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: PT29pt-F1s
; US-08-232-463-14

Query Match 2.2%; Score 47.8; DB 1; Length 7218;


```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/276,452
FILING DATE: 18-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Caruthers, Jennie M.
REGISTRATION NUMBER: 34,464
REFERENCE/DOCKET NUMBER: 27-91A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303)499-8080
TELEFAX: (303)499-8089
TELEX: 49617824
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 1690 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 60..1442
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..38
OTHER INFORMATION: /note= "Nucleotide sequence
OTHER INFORMATION: obtained by PCR which does not overlap with the
OTHER INFORMATION: CDNA clone"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 60..128
OTHER INFORMATION: /note= "Predicted transmembrane
OTHER INFORMATION: segment"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 135..179
OTHER INFORMATION: /note= "Derived amino acid sequence
OTHER INFORMATION: corresponding to the peptide sequence by protein
OTHER INFORMATION: microsequencing"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 135..179
OTHER INFORMATION: /note= "Amino acids 27 to 36, 38,
OTHER INFORMATION: and 40 are identical to that in the peptide
OTHER INFORMATION: obtained by direct microsequencing"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 135..179
OTHER INFORMATION: /note= "Amino acid 26 may also be
OTHER INFORMATION: Ala; 37 and 39 can also be undetermined residues"
US-08-798-744-24

Query Match          1.6%; Score 35.4; DB 2; Length 1690;
Best Local Similarity 61.3%; Pred. No. 0.82; Indels 0; Gaps 0;
Matches 57; Conservative 0; Mismatches 36;

QY      1591 TGACAGTGCAGCTGAGAGAAGGAAGGAAACCCCTCCATGCAGGCCCTCATTTGTGGATTCT 1640
        ||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       1290 TGTATTGTAGTGCTCAATCATGTTTGTAAATTCACAGTAGCATTGTTGGTATTCT 1231
        ||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY      1641 CATCTGGTCTCATTATAGCAGCGCCATTCT 1673
        ||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       1230 CATCTTGATATCAATAATAACTTGCATTT 1198
        ||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 6
US-09-134-001C-745
; Sequence 745, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC-007
```

QY 1407 GACAGGCCAGGAGAGCATCTCAAACTACCA 1438
+ + + + +
Db 83 GCCAGAGCCTGGAGAAGCTGAAGAAGAACCA 114

RESULTS

```

US-08-755-597-23
; Sequence 23, Application US/08755587
; Patent No. 6045997
;
; GENERAL INFORMATION:
;
; APPLICANT: Futreal, Phillip A
; APPLICANT: Wooster, Richard F
; APPLICANT: Ashworth, Alan
; APPLICANT: Stratton, Michael R
;
; TITLE OF INVENTION: Materials and methods relating to the
; identification and sequencing of the BRCA2 cancer
; susceptibility gene and uses thereof.
;
; TITLE OF INVENTION:
;
;

```

/ title of invention: susceptibility gene and uses thereof.
 /
 / number of sequences: 222
 / correspondence address:
 / addresser: Bell Seltzer Park & Gibson
 / street: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107
 /

CITY: Raleigh
STATE: NC
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9617961.9
FILING DATE: 28-AUG-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kenneth D Sibley
REGISTRATION NUMBER: 31.665
REFERENCE/DOCKET NUMBER: 5405-135
INFORMATION FOR SEQ ID NO: 23:

```

/ SEQUENCE CHARACTERISTICS:
/     LENGTH: 964 base pairs
/     TYPE: nucleic acid
/     STRANDEDNESS: double
/     TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)

```

```

FEATURE:
NAME/KEY: CDS
LOCATION: 501..615
FEATURE:
NAME/KEY: exon
LOCATION: 501..615

```

US-08-755-587-23

Query Match 1.5%; Score 32.6; DB 3; Length 964;
Best Local Similarity 46.0%; Pred. No. 4.4;
Matches 110; Conservative 0; Mismatches 129; Indels 0; Gaps 0;

646	CTGTGGGTAACTACATAGACCACAAATGGAAAAGACAAAGTGAAGATCAGCGGATCACTTCC	705
QY		
Db		
105	CTGTGGTCTTACAATGTACACATGTAACACCACAAGAGATAAGTCAGGTATGATTAAAA	164
QY		
165	AACTACTCATCGGCAAGCTGCACAGTGAATCTGCTCTCGATTTTCCATTTTATGGTCAT	224
QY		
Db		

Db 422 ACAATGTTTATCTTGAATACTAGAAATGTTAAATAAAATAAAACTTTAAACAATTT 481
QY 766 TTCTAAATGAAGTCACTGCGCAACTGGGGTTTCATATATCTGGAAGAGTTGTACAT 825
Db 482 CCCCTTTTATCCCACTGATGTGGAGTTTGTTCATACACCAAAATTTGTGAAG 541
QY 826 CGAATGCTCACAGCTACACAGATATAGCTCCTTTAAATGGCAAAATTTTGATCCCAAGT 884
Db 542 GTAATATTCTACCTGGTTTATTTTATGACTAGTAAATGAGAAATTTGACAATAGCT 600

RESULT 10

US-08-755-587-21

; Sequence 21, Application US/08755587

; Patent No. 6045997

; GENERAL INFORMATION:

; APPLICANT: Futreal, Phillip A

; APPLICANT: Wooster, Richard F

; APPLICANT: Ashworth, Alan

; APPLICANT: Stratton, Michael R

; TITLE OF INVENTION: Materials and methods relating to the

; TITLE OF INVENTION: Identification and sequencing of the BRCA2 cancer

; TITLE OF INVENTION: susceptibility gene and uses thereof.

; NUMBER OF SEQUENCES: 222

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Bell Seltzer Park & Gibson

; STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107

; CITY: Raleigh

; STATE: NC

; COUNTRY: USA

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/755,587

; FILING DATE: 25-NOV-1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9523959.6

; FILING DATE: 23-NOV-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9525555.0

; FILING DATE: 14-DEC-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9617961.9

; FILING DATE: 28-AUG-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Kenneth D Sibley

; REGISTRATION NUMBER: 31,665

; REFERENCE/DOCKET NUMBER: 5405-135

; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 1050 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 502..550

; FEATURE:

; NAME/KEY: exon

; LOCATION: 501..550

; US-08-755-587-21

Query Match 1.5%; Score 32.6; DB 3; Length 1050;

Best Local Similarity 46.0%; Pred. No. 4.7;

Matches 110; Conservative 0; Mismatches 129; Indels 0; Gaps 0;

QY 646 CTGTGGTAACTAGACCAATCGAAAAAGACAAAGTGAAGATTCACGGGATCTTCC 705

Db 503 CTGTTGTTCTACAATGTACACATGTACACACCAAGAGATAAGTCAGGTATGATTAATA 562
QY 706 AACACTCACTCGGAGCTGCAAGAGTGAATCTGCTCTCGATTTTCCATTTTATGGTCAT 765
Db 563 ACAATGCTTTTATCTTCTAGATATCTAGAAATGTTAAATAAAATAAAACTTTAACAATTT 622
QY 766 TTCTAAATGAAGTCACTGTCGCAACTGGGGTTTCATATATCTGGAAGAGTTGTACAT 825
Db 623 CCCCTTTTATCCCACTGATGTGGAGTTTGTTCATACACCAAAATTTGTGAAG 682
QY 826 CGAATGCTCACAGCTACACAGATATAGCTCCTTTAAATGGCAAAATTTTGATCCCAAGT 884
Db 683 GTAATATTCTACCTGGTTTATTTTATGACTAGTAAATGAGAAATTTGACAATAGCT 741

RESULT 11

PCT-US94-12912-4/c

; Sequence 4, Application PC/TUS9412912

; GENERAL INFORMATION:

; APPLICANT: UNIVERSITY OF SOUTHERN CALIFORNIA

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR

; TITLE OF INVENTION: TRANSDUCTION OF CELLS

; NUMBER OF SEQUENCES: 4

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: C/O Robbins, Berliner & Carson

; STREET: 201 North Figueroa Street, Fifth Floor

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90012

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patentin Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: PCT/US94/12912

; FILING DATE:

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Spitals, John P.

; REGISTRATION NUMBER: 29,215

; REFERENCE/DOCKET NUMBER: 1920-341

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 977-1001

; TELEFAX: (213) 977-1003

; INFORMATION FOR SEQ ID NO: 4:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 1432 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cdna

; PCT-US94-12912-4

Query Match 1.5%; Score 32.6; DB 5; Length 1432;

Best Local Similarity 46.0%; Pred. No. 5.8;

Matches 110; Conservative 0; Mismatches 129; Indels 0; Gaps 0;

QY 1192 AAAATTACCAATCTCAGCTGTGGAGATGACTCCACTTCCACATGTCCTCCAGTTCAT 1251

Db 940 AATCTTACAAATTTACAACTGAAAGAAATCTTATGTACATGTTCTCTGTTGGGA 881

QY 1252 GGTGTGCGCTTGTGTCTCGCAGATGTTTCAACTGTCAGTGTGGTGGGACCAACT 1311

Db 880 CTTTGTGAAGCCTTCTTCGTCCTGTGTATTAGCCCTCCGGAAGATCATATAGACCA 821

QY 1312 CAAGATGCTCCAGTGGATTTGATCGCCATCGGACGACTGGGTGGACAGTGGATCCCG 1371

Db 820 GAAATATTAGTTCATAGCAGATGATAGATAAGCCTGGAACCTAGAAAGCCCTGGAGTTCGAG 761

QY 1372 GAAGAGGTACAGTCAAAGAGAGATGTGTGAGAAGACAGAGCCAGGAGAGATCTCA 1430

```

Db      760  GCTGTGAATCGGTGCTGGCAACTGGGAGAGAGAGAACCCAGTCTCTGGAGAGGCAACCCA
RESULT 12
US-09-000-094-45
; Sequence 45, Application US/09000094
; Patent No. 6365160
; GENERAL INFORMATION:
; APPLICANT: WEBB, Elizabeth Ann
; MARGETTS, Mary Brigid
; COX, John Cooper
; FRAZER, Ian
; MCMILLAN, Nigel Alan John
; WILLIAMS, Mark Philip
; MOLONEY, Margaret Bridget
; Holland
; EDWARDS, Stirling John
; TITLE OF INVENTION: PAPILLOMAVIRUS POLYPROTEIN CONSTRUCTS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY & LARDNER
; STREET: 3000 K Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/000,094
; FILING DATE: 21-Apr-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/AU96/00473
; FILING DATE: 26-JUL-1996
; APPLICATION NUMBER: AU PN 4439/95
; FILING DATE: 27-JUL-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 017227/0137
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 45:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 4770 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..4761
; SEQUENCE DESCRIPTION: SEQ ID NO: 45:
US-09-000-094-45

Query Match      1.5%; Score 32.6; DB 4; Length 4770;
Best Local Similarity 51.0%; Pred. No. 13;
Matches 77; Conservative 0; Mismatches 74; Indels 0; Gaps

Qy      405  TGAAGAGGGGTAGAGTGGACTCTCAAGCATACACACACAGGTGGGAAAGAAGAAATGTGGA
Db      3234  TGAAGTGAAGCTGGAAGCGGGAACGCGAGGTAGAGAAACATGGCGTACCGGAAAATGGGGG
Qy      465  CCCTTTTAGCGAGTACAGACAAACAGAGCGACATGGGCCAAGCCTCTCCAGAGAGTCCAA
Db      3294  AGATGTCAGGAAGAAGACACAGGAGGGGACATAGAGGGGGAGGAGCAATACAGAGAGCGGGA
Qy      525  AGGGTTTCACTGACCTGCTTACTGGATGACGGA 555

```

```

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(3837)
US-09-462-136-1

Query Match          1.5%; Score 32.4; DB 4; Length 4550;
Best Local Similarity 47.5%; Pred. NO. 14;
Matches 96; Conservative 0; Mismatches 106; Indels 0; Gaps 0;

QY 1689 GTATCACCATCCAACTATCAGCCAGCATCTTCTTCATTAGAGACGCCCAAGCAGATG 1748
DB 1021 GTGTGACAGCCGCTCAACGACGCCCTCAATGCTCGCTGACAGGGTCACAGCAGGACG 962
QY 1749 GCCAGCAATGAAGTTTCGAGAGGGCTCAGGACACCCCTGCCTATGCAAGAAGTTGAACCACT 1808
DB 961 CCTCTCCTTTGTCACTTGCATTTAACAGAAAAAGCTATATTGCTATCGATGGGAGTGTACT 902
QY 1809 TGGAGAGAAAGAGGTTTTATTCTATCAGAGCAGAGTCTAAATAATTTTAGSACAGAGCAGCA 1868
DB 901 CGGAGACAAATACCGTTTCTCTAGCACCCACACTGCAAAAAATGCTCCAAAAAACACAA 842
QY 1869 CCAGTACTGGCTTACAGGTGTT 1890
DB 841 GCAAAACGCCATAGTGTGAT 820

Search completed: June 23, 2003, 22:05:47
Job time : 131 secs

```

```

RESULT 15
US-09-462-136-1/c
; Sequence 1, Application US/09462136
; Patent No. 6426198
; GENERAL INFORMATION:
; APPLICANT: Carstee, et al.
; TITLE OF INVENTION: Genes for Niemann-Pick Type C Disease
; FILE REFERENCE: 4239-53894
; CURRENT APPLICATION NUMBER: US/09/462,136
; CURRENT FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: PCT/US98/13862
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: US 60/051,682
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 4550
; TYPE: DNA

```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 23, 2003, 17:38:49 ; Search time 486 Seconds
(without alignments)
10083.021 Million cell updates/sec

Title: PCT-US02-16639-1

Perfect score: 2176
Sequence: 1 atgtgtctcagttgggggc.....taggtgcagggttgcaaaaa 2176

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

- 1: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
- 21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
- 22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
- 23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
- 24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1935.6	89.0	2009	24	ABL92084
2	1935.6	89.0	2010	24	ABL92137
3	1478.2	67.9	2817	22	AAH52224
4	1476.6	67.9	2594	22	AAH46160
5	1440.4	66.2	3095	22	AAH23066
6	1423.8	65.4	2157	24	ABL92080
7	1423.8	65.4	2159	24	ABL92088
8	1423.4	65.4	2557	22	AAH87054
9	1238	56.9	1590	22	AAH23067

C	10	1195.2	54.9	2668	22	AAI60009	Human polynucleoti
C	11	1195.2	54.9	2668	22	AAI60010	Human polynucleoti
C	12	1195.2	54.9	2668	22	AAH75398	Human polynucleoti
C	13	1195.2	54.9	2668	22	AAH23063	Stem cell growth f
C	14	1195.2	54.9	2668	22	AAH23064	Stem cell growth f
C	15	1165.2	53.5	2275	22	AAI58223	Human polynucleoti
C	16	1031.6	47.4	1351	22	AAH23068	Stem cell growth f
C	17	951.8	43.7	1179	22	AAH23065	Stem cell growth f
C	18	806	37.0	1252	22	AAH14197	Human cDNA sequenc
C	19	727.8	33.4	1101	21	AAH74708	Human ORFX ORF263
C	20	393.6	18.1	2320	24	ABL92103	Human Tumour Endot
C	21	393.6	18.1	4640	24	ABL92077	Human Tumour Endot
C	22	384.4	17.7	494	22	AAH23054	Stem cell growth f
C	23	365.6	16.8	2833	24	ABL92083	Mouse tumour Endot
C	24	365.6	16.8	2840	24	ABL92136	Mouse tumour Endot
C	25	347.6	16.0	1201	21	AAH77340	Human ORFX ORF2895
C	26	343.6	15.8	406	22	AAH23062	Stem cell growth f
C	27	333	15.3	820	22	AAH93283	Human tumour endot
C	28	333	15.3	820	22	AAH93285	Human tumour endot
C	29	328.6	15.1	392	22	AAH23051	Stem cell growth f
C	30	328.4	15.1	412	22	AAH23058	Stem cell growth f
C	31	322.4	14.8	498	22	AAH23048	Human immune/haema
C	32	321.8	14.8	1141	22	AAH61650	Human cDNA clone (
C	33	318.6	14.6	479	22	AAH05765	Stem cell growth f
C	34	298	13.7	366	22	AAH23042	Stem cell growth f
C	35	295	13.6	382	22	AAH23061	Stem cell growth f
C	36	290	13.3	417	22	AAH23052	Stem cell growth f
C	37	275.2	12.6	416	22	AAH23060	Stem cell growth f
C	38	269.2	12.4	430	22	AAH23056	Stem cell growth f
C	39	266.6	12.3	348	22	AAH22512	Human breast cance
C	40	266	12.2	334	22	AAH23043	Stem cell growth f
C	41	265.6	12.2	347	22	AAH13643	Human breast cance
C	42	260.6	12.0	415	22	AAH23053	Stem cell growth f
C	43	231.4	10.6	534	22	AAH93287	Human tumour endot
C	44	229.8	10.6	323	24	ABN17873	Human ORFX polynuc
C	45	217.8	10.0	422	22	AAH23044	Stem cell growth f

ALIGNMENTS

RESULT 1

ABL92084
ID ABL92084 standard; cDNA; 2009 BP.

XX AC ABL92084;

XX DT 30-MAY-2002 (first entry)

XX DE Mouse Tumour Endothelial Marker polynucleotide SEQ ID NO 185.

XX KW Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
KW normal endothelial marker; pan-endothelial marker; immunostimulant;
KW antiangiogenic; tumour; neoangiogenesis; vascularised tumour;
KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
KW psoriasis; gene; ss.

XX OS Mus musculus.

XX PN WO200210217-A2.

XX PD 07-FEB-2002.

XX PF 01-AUG-2001; 2001WO-US24031.

XX PR 02-AUG-2000; 2000US-222599P.

XX PR 11-AUG-2000; 2000US-224360P.

XX PR 11-APR-2001; 2001US-282850P.

XX PA (UJJO) UNIV JOHNS HOPKINS.

XX PI St Croix B, Kinzler KW, Vogelstein B;

Db 1741 CAGAGGGCGAGGATTTCTGGACAGCCGACCCAGAACATTTGAAGAAACTCAG 1800
QY 2035 ACTTGTAAGACACCATGTCAATGATTAAGAAATCCCTAGTGAATGACATCCATGG 2094
Db 1801 ACTTGTAAGACACCATGTCAATGATTAAGAAATCCCTAGTGAATGACATCCATGG 1860
QY 2095 TTCACAAGAACATCTCCGGTGGACTTGCACAGGAGTGTGACGAGATGACATGCTTTTGG 2154
Db 1861 TTCACAAGAACATCTCCGGTGGACTTGCACAGGAGTGTGACGAGATGACATGCTTTTGG 1920
QY 2155 TTTAGTGCAGGGTTGCAAAA 2176
Db 1921 TTTAGTGCAGGGTTGCAAGA 1942

RESULT 2
ABL92137
ID ABL92137 standard; cDNA; 2010 BP.
XX
AC ABL92137;
XX
DT 30-MAY-2002 (first entry)
XX
DE Mouse Tumour Endothelial Marker polynucleotide SEQ ID NO 298.
XX
KW Human; mouse; rat; TEM; tumour endothelial marker; NEM; PEM; cytostatic;
KW normal endothelial marker; pan-endothelial marker; immunostimulant;
KW antiangiogenic; tumour; neovascularization; vascularised tumour;
KW polycystic kidney disease; diabetes; retinopathy; rheumatoid arthritis;
KW psoriasis; gene; ss.
XX
OS Mus musculus.
XX
PN WO200210217-A2.
XX
PD 07-FEB-2002.
XX
PF 01-AUG-2001; 2001WO-US24031.
XX
PR 02-AUG-2000; 2000US-222599P.
PR 11-AUG-2000; 2000US-224360P.
PR 11-APR-2001; 2001US-282850P.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX St Croix B, Kinzler KW, Vogelstein B;
XX
XX WPI; 2002-291856/33.
DR P-PSDB; ABB90784.
XX
PT An isolated molecule comprising an antibody variable region which
PT specifically binds to an extracellular domain of a tumor endothelial
PT marker (TEM) protein, useful for inhibiting tumor growth -
XX
XX Disclosure; Page 302-303; 331pp; English.
PS
XX
CC The invention relates to an isolated molecule comprising an antibody
CC variable region which specifically binds to an extracellular domain of a
CC tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
CC ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
CC proteins have cytostatic, immunostimulant and antiangiogenic activity.
CC They are useful for inhibiting tumour growth, neoangiogenesis in
CC subjects bearing a vascularised tumour, polycystic kidney disease,
CC diabetic retinopathy, rheumatoid arthritis and psoriasis. Human, mouse
CC and rat TEM genes and the encoded proteins (ABL92075-ABL92141 and
CC ABB90721-ABB90789) are disclosed, as are marker oligonucleotide
CC sequences: tumour endothelial markers (TEM) ABL91996-ABL92041 and
CC ABL92143-ABL92191; normal endothelial markers (NEM) ABL92042-ABL92074;
CC and pan-endothelial markers (PEM) ABL91903-ABL91995.
XX
XX Sequence 2010 BP; 625 A; 461 C; 475 G; 449 T; 0 other;
SQ

Query Match 89.0%; Score 1935.6; DB 24; Length 2010;

Best Local Similarity 99.8%; Pred. No. 0;
Matches 1938; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 235 GAGAGAGTCCGGCAGCGCATGGCAAGGTTCGGAGGGCCGACCTGGCCGAGCAGGA 294
Db 1 GAGAGAGTCCGGCAGCGCATGGCAAGGTTCGGAGGGCCGACCTGGCCGAGCAGGA 60
QY 295 GTATGTTACTTTGTCACCTTTTAAACAGACGGTTCAGTTCGCCACGGGGAGCCCTGGA 354
Db 61 GTATGTTACTTTGTCACCTTTTAAACAGACGGTTCAGTTCGCCACGGGGAGCCCTGGA 120
QY 355 CACCATACCAATGATTGATTAAGATTACAACCGCTTTCCCTTGGATGAAGAGGGG 414
Db 121 CACCATACCAATGATTGATTAAGATTACAACCGCTTTCCCTTGGATGAAGAGGGG 180
QY 415 GTAGAAGTGGACTCTCAAGCATACAACACAGGTGGAAGAAATGTGACCCCTTTTAA 474
Db 181 GTAGAAGTGGACTCTCAAGCATACAACACAGGTGGAAGAAATGTGACCCCTTTTAA 240
QY 475 GCAGTAGACACAACAGAGCCAGCATGGCCAAAGCTCTCCAGAGTCCAAAGGGTTCAC 534
Db 241 GCAGTAGACACAACAGAGCCAGCATGGCCAAAGCTCTCCAGAGTCCAAAGGGTTCAC 300
QY 535 GACCTGCTACTGGATGACGAGCAGGACAATAACCCAGATAGAGGAGGACACGGATCAC 594
Db 301 GACCTGCTACTGGATGACGAGCAGGACAATAACCCAGATAGAGGAGGACACGGATCAC 360
QY 595 AATTACTACATTTCTCGATATATGTTCCAGCGGATTTCTGCCACCCGGGATCTGTGGGTT 654
Db 361 AATTACTACATTTCTCGATATATGTTCCAGCGGATTTCTGCCACCCGGGATCTGTGGGTT 420
QY 655 AACATAGACCAATGGAAGAAAGACAAGTGAAGATTCACGGGATCTTCCAAACACTCAT 714
Db 421 AACATAGACCAATGGAAGAAAGACAAGTGAAGATTCACGGGATCTTCCAAACACTCAT 480
QY 715 CGGCAAGTGCAGAGTGAATCTGTCCTTCGATTTTCCATTTTATGTCATTTTCTAAAT 774
Db 481 CGGCAAGTGCAGAGTGAATCTGTCCTTCGATTTTCCATTTTATGTCATTTTCTAAAT 540
QY 775 GAAGTCACTGTGGCAACTGGGGTTTCATATATATGAGAGTGTGACATCGAATGCTC 834
Db 541 GAAGTCACTGTGGCAACTGGGGTTTCATATATATGAGAGTGTGACATCGAATGCTC 600
QY 835 ACAGCTACACAGTATATAGTCTCTTTAATGCAAAATTTTGATCCCATGTATCCAGAAAT 894
Db 601 ACAGCTACACAGTATATAGTCTCTTTAATGCAAAATTTTGATCCCATGTATCCAGAAAT 660
QY 895 TCAACTGTCAAGTATTTGATAATGGCAGCTCTGTTGTCAGTGGGACCATGTCAC 954
Db 661 TCAACTGTCAAGTATTTGATAATGGCAGCTCTGTTGTCAGTGGGACCATGTCAC 720
QY 955 CTGCAGGATATTAACAACCTGGGAGCTTTCATTTCCAGGCCACACTCCTCATGGACGG 1014
Db 721 CTGCAGGATATTAACAACCTGGGAGCTTTCATTTCCAGGCCACACTCCTCATGGACGG 780
QY 1015 CCATCATCTTTGGATACAAGAAATCCCTGTCCTGTCACACAGATAAGTCTACCAAC 1074
Db 781 CCATCATCTTTGGATACAAGAAATCCCTGTCCTGTCACACAGATAAGTCTACCAAC 840
QY 1075 CATCCAGTGAAGTCCGGTGTGTCGATCATTTGTCGTGGTCCACAGATCCAGCAATA 1134
Db 841 CATCCAGTGAAGTCCGGTGTGTCGATCATTTGTCGTGGTCCACAGATCCAGCAATA 900
QY 1135 CCCAATGTCGAAGAGAACAAATTTATGAATATCCAGTAGAAGTACAAATGTCAAA 1194
Db 901 CCCAATGTCGAAGAGAACAAATTTATGAATATCCAGTAGAAGTACAAATGTCAAA 960
QY 1195 ATTACCAATCTCAGCTGTGGAGATGACTCCACTTCCACATGTCCTCCAGTTCAATGGT 1254
Db 961 ATTACCAATCTCAGCTGTGGAGATGACTCCACTTCCACATGTCCTCCAGTTCAATGGT 1020
QY 1255 TGTGGCCCTTGTGTCCTTCGAGATTTGTTTCAACTGCAAGTGGTGACAGAAATCTCAA 1314
Db 1020 TGTGGCCCTTGTGTCCTTCGAGATTTGTTTCAACTGCAAGTGGTGACAGAAATCTCAA 1314

CC leukemia, hemophilia, and degenerative diseases like Alzheimer's disease.
CC They may also be utilized to generate new tissues and organs that may aid
CC patients in need of transplants. They can also be used as nutritional
CC supplements. The present sequence represents a stem cell growth factor-
CC like polypeptide encoding cDNA.

Sequence 3095 BP; 950 A; 687 C; 654 G; 804 T; 0 other;

Query Match	66.28;	Score 1440.4;	DB 22;	Length 3095;
Best Local Similarity	84.3%;	Pred. No. 0;		
Matches 1700;	Conservative	0;	Mismatches 291;	Indels 25; Gaps 6;

168	CGTGTGCGCCCATCCCGCAGGATACCCCGGAGCCAGGGTCTCAAGAAAAAATTCGTTG	227
QY		
35	CGTTTGGCGCGGTGCTGCCCTATTTCATCTGGGAGCCCCCGAGACCGCGGCAAGGACTGGCG	94
Db		
228	GGCAGGGAGAGAGGTGCGCGCAGCGGCATGGCAAGTTTCGGAGGGCGGACCTTGGCGCGC	287
QY		
95	GCTGGGTTAGGAGGTGGCGGCGGCATGGCGAGGTTCCCGAAGCGCGACCTTGGCGCGC	154
Db		
288	ACGAGGATTTATGTTACTTTTGCATTTTTACAGACCGGTTTCCAGTTTCGCCACAGGGGA	347
QY		
155	TCGAGGATTTATGTTACTTTTGCACATCTCTACGGACCAAGTTTCAAGTTTCGCCGATGGGAA	214
Db		
348	GCGTGGACACCATACCAATGATTGGATTTATGAAGTTTACAAACGCTTTTCTCTGGGAATGA	407
QY		
215	ACCCGCGACCAATCCTTGATTGGCAGTATGGAGTTACTCAGGCGCTTCCCTCACACAGA	274
Db		
408	AGAGGGGTAGAGTGAGCTCTCAAGATACAAACCACAGGTGGGAAAGAAATGTGGACCC	467
QY		
275	GGAGAGGTGGAGTTGATTTCACACGCTACAGCCACAGGTGGGAAAGAAATTTGGACTT	334
Db		
468	TTTTAAGGCAGTAGACACAAACAGAGCGCAGCATGGGCCAAAGCTCTCCAGAGTCCAAAGG	527
QY		
335	TCTCAAGCGGTAGACACGAAACGAGCGAGCGTCGGCCAAAGACTCTCTGAGCCACAGAG	394
Db		
528	GTTTACTGACCTGTTACTGGATGACGGGACAGACAAATAACCCAGATAGAGGAGGACAC	587
QY		
395	CYTTCACAGCCTGCTGTGGTATGGCGAGGACAAATAACACTCAGATCGAGGAGGATAC	454
Db		
588	GGATCACAAATTTACTACATTTCTCGGATATATGTCTCAGGGGATCTCTGCCAGCGGGATCT	647
QY		
455	AGACCACAAATTTACTATATCTCGAATATATGTCTCATCTGATCTGCCACCGGGATTT	514
Db		
648	GTGGGTTTAACATAGACCAATATGAAAAAGACAAAGTGAAGATTCACGGGATACTTTCCAA	707
QY		
515	ATGGGTGAACATAGACCAATATGAAAAAGATAAGTGAAGATTCATGGAATATTGTCCAA	574
Db		
708	CACCTATCGGCAAGCTCCAAGAGTGAATCTGTCTTCGATTTTCCATTTTATGTGCTATTT	767
QY		
575	TACTCATCGGCAAGCTCCAAGAGTGAATCTGTCTTCGATTTTCCATTTTATGTGCCACTT	634
Db		
768	TCTAATTAAGCTCACTGTGGCAACTGGGGTTTCATATATCTCGAGAAGTTGTACATCG	827
QY		
635	CCTAGTGAATCACTGTGGCAACCGGGGTTTCATATACACTGGAGAAGTCGTACATCG	694
Db		
828	AATGCTCACAGCTACACAGTATATAGTCTCTTTAATGGCAAAATTTTGATCCCGATGATC	887
QY		
695	AATGCTAACGCCACACAGTACATAGCACTTTAATGGCAAAATTTTCGATCCCGATGATC	754
Db		
888	CAGAAATTCACCTGTCCAGATATTTTGATATGGCACAGCTCTTTGTTCAGTGGGACCA	947
QY		
755	CAGAAATTCACCTGTCCAGATATTTTGATATGGCACAGCAGCTTTGTGTCAGTGGGACCA	814
Db		
948	TGTCACCTCGAGGATTAATTACAACTGGGAAGCTTTCATTTCCAGGCCACACTCCCTCAT	1007
QY		
815	TGTATATCTCCAGGATTAATTATACCTGGGAAGCTTTCATTTCCAGGCCAACCCCTGCTCAT	874
Db		
1008	GGACGGGCGCATCATCTTTGGATACAAAGAAATCCCTGTCTTGTGTCACACAGATAAGTTC	1067
QY		
875	GGATGGAGGAATCATCTTTGGATACAAAGAAATTTCTGTCTTTGGTCACACAGATAAGTTC	934
Db		
1068	TACCACCACTCCAGTGAAGTCGGGTTGTCTGATGCTATTTGTCTGTGGTCCACAGGATCCA	1127
QY		

	935		AACCAATCATCCAGTGAAGTCGGACTGTCGGATGATTGTCTTGTTGCCAGGATCCA	994
Db				
Qy	1128	GCAAAATACCCAAATGTTCGAAGAAGAACAAATTTATGAATATCACCGAGTAGAAGTACAAGT	1187	
Db				
Db	995	ACAAATTCCCAATGTTCGAAGAAGAACAAATTTATGAATACCACCGAGTAGAGCTACAAGT	1054	
Qy	1188	GTCCAAAATATCCACACATCTCAGCTGTGGAGTAGCTCCACTTCCCACATGCTCCAGTT	1247	
Db				
Db	1055	GTCAAAAATATCCACACATTTCCGGCTGTGGAGATGACCCCATTAACCCACATGCCTCCAGTT	1114	
Qy	1248	CAATGGTTGTGGCCCTTGTGTCTCGCAGATGTGTTTTCAACTCAGCTGTGTCGACAA	1307	
Db				
Db	1115	TAAACAGATGTGGCCCTGTGTATCTCTCAGATGTGCTTCAACTCGTTGGTAGTAA	1174	
Qy	1308	ACTTCAAAGATGCTCCAGTGGATTGATCCCATCGGCAGGACTGGTGGACAGTGGATG	1367	
Db				
Db	1175	ACTTCAAAGATGTTCCAGTGGATTGATCGTATCGGCAGGACTGGTGGACAGTGGATG	1234	
Qy	1368	CCGGGAAGAGTACAGTCAAAGAGAGATGTGTGAGAAGACAGACCAGGAGAGA--CC	1424	
Db				
Db	1235	CCCTGAAG-----AGTCAAAGAGAGAGATGTGTGAAGATACAGAACCAGTGGAAACTTC	1288	
Qy	1425	ATCTCAAATACTACCAGACCTCCCAACAGACCACCATGCAATTCAGGGTCTTGACCCAC	1484	
Db				
Db	1289	TCTTCGACCCACCAACCATAGGAGGAGACACCCACCAGTTCAGSGTCTTAATACAC	1348	
Qy	1485	CAGGAGAGCTGTGACATCTCAGATGCGTACAGCGCTGCCTACAGAAGATGACACGAAGT	1544	
Db				
Db	1349	CAGAAGACAGTGAATCTTCAGTITCCACAGCCTCCCTACAGAAGATGATCCCAAGT	1408	
Qy	1545	AGCCCTACATCTCAAAGACAGTGGAGCCTCCACAGATGACAGCTGCAGCTGAGAAGAAAGG	1604	
Db				
Db	1409	AGCACTACATCTAAAGATTAATGGAGCTTCTACAGATGACAGTGCAGCTGAGAAGNAGG	1468	
Qy	1605	AGGAACCTCATGACAGGCTCATTTGTTGAATCTCATCTTGGTCTCTCAATTAAGAGC	1664	
Db				
Db	1469	GGGAACCTCCACGCTGGCCTCATCGTTGGAATPCTCATCTCTGGTCTCTATGTAGGCC	1528	
Qy	1665	GGCCATTCTGGTGACAGTGATATGTATCACCATCCAAATCAGCAGCCAGCATCTCTCTT	1724	
Db				
Db	1529	AGCCATTCTTGTGACAGTCTATATGATATCACCAACCCAAACATCAGCAGCCAGCATCTCTT	1568	
Qy	1725	CATTGAGAGAGCCCCAGCAGATGGCCACGATGAAGTTTCCAAGAGGCTCAGACACCC	1784	
Db				
Db	1589	TATTGAGAGAGCCCCAAGCAGATGGCCTCGATGAAGTTTAGAAGAGGCTCTGACATCC	1648	
Qy	1785	TGCCTATGCAGAAAGTTGAACACAGTTGGAGAGAAAGAGTTTATTTGTATCAGAGCAGTG	1844	
Db				
Db	1649	TGCCTATCTGAAGTTGAACCCAGTTGGAGAGAAAGAGGCTTTATTGTATCAGAGCAGTG	1708	
Qy	1845	CTAAAAATT-TAGACACAGAGCAGCACCCAGTACTGGCTTACAGGTTTAAAGACTTAAACTT	1903	
Db				
Db	1709	CTAAAAATTCTAGACACAGAACACACAGTACTGGTTTACAGGTTTAAAGACTTAAATTT	1768	
Qy	1904	TGCTTATTGCATTTAAGACAACAGACACACACCCACAACACCAAGAGAGGCCCTAA	1963	
Db				
Db	1769	TGCCTATACCTTTAAGACAACAAACAACA-----CACACACAAACAGCTCAA	1819	
Qy	1964	ACTGCTGTAGACAGAGGGCGACGAGATTTCTGGACAGCCAGCCGACG-----ACAT	2018	
Db				
Db	1820	GCTGCTGTAGCCTGAA-GAAGACAAGATTTCTGGACAGCTCAGGCCAGGAAACAAGGG	1878	
Qy	2019	TGAAGAGAAAACCTCAGACTTGTACAAGACACCATGTACAAATGATTAAAGAAATCCCTAGT	2078	
Db				
Db	1879	TAAACAAAAAACTAAAACTTTATACAAGATACCATTTTACACTGAACATAGAATTCCTAGT	1938	
Qy	2079	GGAATGACATCCATGGTTTACAGGAGACATCCCGTGGACTTGCACGAGTGTGACGAG	2138	
Db				
Db	1939	GGAATGTCATCTATAGTTCTACTCGGRACATPCTCCGTGGACTTATCTGAAGTATGACAAG	1998	
Qy	2139	ATGACCATGCTTTTGGTTTATAGTGCAGGGTTGCAAA	2174	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

121	GATTGGCAGTATGGAGTTACTCAGGCCTTCCCTCACACAGAGGAGGAGTGGAGTTGAT	180
427	TCCTCAAGCATACAAACACAGAGTGGAAAGAAATGTGGACCCCTTTTAAAGCGAGTAGACACA	486
181	TCACACGCGTACAGCCACAGGTGGAAAGAAATCTGGACTTTCTCAAGGCGGTAGACACG	240
487	AACAGAGCCAGCATGGCCCAAGCCTCTCCAGAGTCCAAAGGTTCCACAGGTTCTACATGACTGCTACTG	546
241	AACCGAGCAAGCGTCGGCCAAAGACTCTCTGAGCCCAAGAGCTTCACAGACCTGCTGCTG	300
547	GATGACGGCAGGACAAATAACACCCAGATAGAGGAGGACACGGATCACAATTTACTACAT	606
301	GATGATGGCAGGACAAATAACACTCAGATCGAGGAGGATACAGACCAACAATTTACTATATA	360
607	TCCTCGGATATATGTTCCAGCGGATCTGCCAGCCGGATCTGTGGTTAAACATAGACCAA	666
361	TCCTCGAATATATGGTCCATCTGATCTGCCAGCCGGATTTATGGTGAACATAGACCAA	420
667	ATGGAAAAAGACAAAGTGAAGATTACAGGGATCTTTCCAAACATCTCGCGAAGCTGCA	726
421	ATGGAAAAAGATAAAGTGAAGATTTCATGGAATATTTGCCAATACTCATCGGCAAGCTGCA	480
727	AGAGTGAATCTGCTTCGATTTTCCATTTTATGGTCAATTTTCTAAATGAAGTCACTGTG	786
481	AGAGTGAATCTGCTTCGATTTTCCATTTTATGGCCACTTCTCTAGTGAATCACTGTG	540
787	GCAACTGGGGTTTCATATATCTGGAGAAAGTTGTATCATCGAATGCTCACAGCTACACAG	846
541	GCAACCGGGGTTTCATATACCTGGAGAGTCTGTACATCGAATGCTACACAGCTACACAG	600
847	TATATAGTCTCTTTAATGSCAAATTTTGATGCCAGTGTATCCAGAAATTCACACTGTGCA	906
601	TACATAGCACTTTAATGGCAAAATTCGATCCAGCTGTATCCAGAAATTCACACTGTGCA	660
907	TATTTGTATATGGCACAGCTCTTTGTGTCACAGTGGGACCATGCTCCACTGCAGGATAT	966
661	TATTTGTATATGGCACAGCTTTGTTGTCACAGTGGGACCATGCTCCACTGCAGGATAT	720
967	TACAACCTGGAGCTTCACATTCAGGGCCACACTCTCTCATGGACGGGCGATCACTTTT	1026
721	TATAACCTGGAGCTTCACATTCAGGGCAACCTCTCTCATGGATGGAGGAATCACTTTT	780
1027	GGATACAAAGAAATCCCTGCTTGGTTCACACATAGTCTTACCACCAATCCAGTGA	1086
781	GGATACAAAGAAATTCCTGCTTGGTTCACACATAGTCTTACCACCAATCATCCAGTGA	840
1087	GTCGGGTTGTCTGATGCAATTTGCTGGTCCACAGGATCCAGCAAAATACCAGTTCGA	1146
841	GTCGGACTGTCGATGCAATTTGCTGGTCCACAGGATCCACAAATTCAGATGTCGA	900
1147	AGAGAAACAATTTATGATATATCAACCGAGTGAAGTACAAATGTCCAAATTTACCAATC	1206
901	AGAAGAAACAATTTATGATATATCAACCGAGTGAAGTACAAATGTCCAAATTTACCAATC	960
1207	TCAGCTGTGGAGATGCTCCACTTCCACATGCTCCAGTTCATAGTTGTGTGCGCCCTGT	1266
961	TCGGCTGTGGAGATGACCCCAATTCACCAATGCTCCAGTTTACAGATGTGCGCCCTGT	1020
1267	GTGTCCTCCAGATTTGGTTTCACTGCAGTTGGTGGACGAAATTCAGAGATGCTCCAGT	1326
1021	GTATCTTCTCAGATTTGGCTTCAACTGCAGTTGGTGTAGTAAATTTCAAGATGTTCCAGT	1080
1327	GGATTTGATCGCCATCGCAGGACTGGGTGGACAGTGTGATGCGGAGAGGTACAGTCA	1386
1081	GGATTTGATCGTCATCGCGAGGACTGGGTGGACAGTGTGATGCGGAGAGGTAGTCTT	1134
1387	AAAGAGAAAGATGTGTGAGAAGACAGACGAGGAGAGA---CATCTCAAACTACACGACC	1443
1135	AAAGAGAAAGATGTGTGAGAATACAGAACCACTGGAAACTTCTTCTCGAACCAACCAACC	1194
1444	TCCCACAGCACCACCATTCATTTAGGTTCTGTACACCAACCGAGAGAGCTGTGACATCT	1503
1195	ATAGGAGGCGCAACCCAGTTCAGGTTCTACTACCCAGAGAGAGGAGAGTGTCTCT	1254

XX	02-AUG-2000; 2000US-222599P.
PR	11-AUG-2000; 2000US-224360P.
PR	11-APR-2001; 2001US-282850P.
XX	(UTVJ) UNIV JOHNS HOPKINS.
XX	
XX	St Croix B, Kinzler KW, Vogelstein B;
PI	WPI; 2002-291856/33.
DR	P-PSDB; ABB90734.
XX	
PT	An isolated molecule comprising an antibody variable region which
PT	specifically binds to an extracellular domain of a tumor endothelial
PT	marker (TEM) protein, useful for inhibiting tumor growth -
XX	
PS	Disclosure; Page 153-154; 33lpp; English.
XX	
CC	The invention relates to an isolated molecule comprising an antibody
CC	variable region which specifically binds to an extracellular domain of a
CC	tumour endothelial marker (TEM) protein selected from ABB90732, ABB90740,
CC	ABB90749, ABB90750 and ABB90769. The antibodies which bind to TEM
CC	proteins have cytostatic, immunostimulant and antiangiogenic activity.
CC	They are useful for inhibiting tumour growth, neovascularogenesis in
CC	subjects bearing a vascularised tumour, polycystic kidney disease,
CC	diabetic retinopathy, rheumatoid arthritis and psoriasis. Human, mouse
CC	and rat TEM genes and the encoded proteins (ABL92075-ABL92141 and
CC	ABB90741-ABB90789) are disclosed, as are marker oligonucleotide
CC	sequences; tumour endothelial markers (TEM) ABL91996-ABL92041 and
CC	ABL92143-ABL92191; normal endothelial markers (NEM) ABL92042-ABL92074;
CC	and pan-endothelial markers (PEM) ABL91903-ABL91995.
XX	
SQ	Sequence 2159 BP; 696 A; 490 C; 463 G; 510 T; 0 other;
	Query Match 65.4%; Score 1423.8; DB 24; Length 2159;
	Best Local Similarity 85.7%; Pred. No. 0;
	Matches 1560; Conservative 0; Mismatches 252; Indels 25; Gaps 6;
QY	247 GCACGCGGCATGGCAAGGTTCGCGAGGCCGCGACCTGGCGCAGCAGGAGTTATTGTTACTT 306
Db	1 GCGCGCGGCATGGCGAGGTTCGCGAAGGCCGCGACCTGGCGCTGCAGGAGTTATTGTTACTT 60
QY	307 TGTCACATTTTTAACAGACCGGTTCCAGTTTCGCCACGCGGGAGCCCTGGACACCATACCAAT 366
Db	61 TGGCACATTTCTTCGCGACCAGTTTCAGTTTCGCGGATGGGAAMCCC GGAGACCAATCCTT 120
QY	367 GATTGGATTTATGAAGTTACAACGCTTTTCCTTGGAATGAAGAGGGGTAGAGTGGAC 426

427	QY	TCTCAGCATACACACAGGTGGAAAAGAAATGTGGACCCCTTTTAAGCCAGTAGACACA	486
181	Db	TCACACGGGTACAGCCACAGGTGAAAAGAAATCTTGGACTTTCTCAGGCCGTAGACAG	240
487	QY	AACAGAGCCAGCATGGCCGAAGCCTCTCCAGAGTCCAAAAGGTTCACTGACCTGCTACTG	546
241	Db	AACCGAGCAACGCTCGGCCAAGACTCTCTGAGCCCCAGAAGCTTCACAGAGCTGCTGCTG	300
547	QY	GATGACCGACAGGACAAATACACCCAGATAGAGGAGGACACAGCATACAAATTTACTTACATT	606
301	Db	GATGATGGCCAGGACAAATACACTCAGATCGAGGAGGATACAGACCCAAATTTACTATATA	360
607	QY	TCTCGGATATATGTTCCAGCGGATTTGCCAGCCGGGATCTGTGGTTAAACATAGACCAA	666
361	Db	TCTCGAATATATGTTGCCATCTGATCTGCCAGCCGGGATTTATGGGTGAACATAGACCAA	420
667	QY	ATGGAAAAGACAAGTGAAGATTCAAGGGATACTTTCCAAACACTCATCGGCCAAGCTGCA	726
421	Db	ATGGAAAAGATAAAGTGAAGATTCATGGAAATATTGTCCTCACTCATCGGCCAAGCTGCA	480
727	QY	AGAGTGAATCTGTCCTTCGATTTTCCATTTTATGGTCATTTTCTAAATGAAGTCACTGTG	786
481	Db	AGAGTGAATCTGTCCTTCGATTTTCCATTTTATGGCACTTCTCAGGTGAATCACTGTG	540

Qy	787	GCAACTGGGGGTTTCATATATAC	TGTGAGAAAGTTGTACATCGAATGCTCACAGCTACACAG	846
Db	541	GCAACCGGGGGTTTCATATACACT	TGGAGAAGTCGTACATCGAATGCTAACACGCCACACAG	600
Qy	847	TATATAGCTCCCTTAAATGCGAAAT	TTTGTATCCAGTGTATCCAGAAATTCACACTGTCTCAGA	906
Db	601	TACATAGCACTTTAAATGCGAAAT	TTTCGATCCAGTGTATCCAGAAATTCACACTGTCTCAGA	660
Qy	907	TATTTTGTAAATGGCACAGCTCT	TGTGTTCAGTGGGAACCATGTCCACCTGCAGGATAT	966
Db	661	TATTTTGTAAATGGCACAGCACT	TGTGTTCAGTGGGAACCATGTACATCTCCAGGATAT	720
Qy	967	TACAACCTGGGAAGCTTCACAT	TTCAGGCGCACACTCCTCATGGACGGGCGCATCATCTTT	1026
Db	721	TATAAGCTGGGAAGCTTCACAT	TTCAGGCGAACCTGCTCATGGATGGAGAAATCATCTTT	780
Qy	1027	GGATACAAAGAAATCCCTGCT	TGTGGTCCACAGATAAGTTCACCAACCATCCAGTGAA	1086
Db	781	GGATACAAAGAAATCCCTGCT	TGTGGTCCACAGATAAGTTCACCAATCATCCAGTGAA	840
Qy	1087	GTGCGGTTGTCTGATGCAT	TGTGCGTCCACAGATCCAGCAAAATACCAATGTTCGA	1146
Db	841	GTGCGACTGCCGATGCA	TTTGTGTTGCCACAGATCCACAAATTCOCAATGTTCGA	900
Qy	1147	AGAGAACAATTTATGAATAT	CACAGTAGAACTACAAATGTCCAAAATTACCAACATC	1206
Db	901	AGAAGAACAATTTATGAAT	ATACCAGTAGAGCTACAAATGTCAAAATTACCAACAT	960
Qy	1207	TCAGCTGTGAGATGACTCC	ACATGCCACATGTCCAGTTTCAATGGTTGTGGCCCTGT	1266
Db	961	TCGGCTGTGAGATGACCC	CAATTACCCACATGCCCTCCAGTTTAAACAGATGTGGCCCTGT	1020
Qy	1267	GTGTCCTCGGAGATGTG	TTTCAACTCGAGTTGTGCAGCAAACTTCAAAGATGTCTCCAGT	1326
Db	1021	GTATCTTCTCAGATGTG	CTTCAACTCGAGTTGTGTAGTAAACTTCAAAGATGTCTCCAGT	1080
Qy	1327	GGATTTGATCGCATCGG	CAGGACTGGGTGGACAGTGGATGCCGGAAGAGGTACAGTCA	1386
Db	1081	GGATTTGATCGTCATCG	GAGACTGGGTGGACAGTGGATGCCCTGAAGTGCCTGAAG-----AGTCA	1134
Qy	1387	AAAGAGAAGATGTGTGA	AGACAGACCCAGGAGAGA---CATCTCAAACACTACCAGACC	1443
Db	1135	AAAGAGAAGATGTGTGAAT	ACAGACCCAGTGGAAACTTCTTCTCGAAGCACCAACAGC	1194
Qy	1444	TCCACACAGCACCCAT	GCATTCAGGCTCCTCACCACACACAGGAGAGTGTGACATCT	1503
Db	1195	ATAGGACGACACCC	AGCTTCAGGGTCTTACTTACCACAGAGACGATGACTTCT	1254
Qy	1504	CAGATGCTTACCAGCT	GCCTACAGAGATGACACGAAGATAGCCCTACATCTCAAGAC	1563
Db	1255	CAGTTTCCCACAGCT	CCCTACAGAAGATGATACCAAGATAGCACTTACATCTTAAAGAT	1314
Qy	1564	AGTGGACCTCCACAG	ATGACATGACGTGCAGCTGAGNAGNAGGAGAGACCTCCATGACGC	1623
Db	1315	AATGGAGCTTCTACAG	ATGACATGACGTGCAGCTGAGNAGNAGGAGAGACCTCCAGCTGGC	1374
Qy	1624	CTCATTTGTGGAATCT	TCATCTTGGTCCCTCATTTATAGCAGCGGCCATTTCTGTTGACAGTG	1683
Db	1375	CTCATCTTGGATCT	TCATCTTGGTCCCTCATTTAGTCCACAGCCATCTTGTGTGACATC	1434
Qy	1684	TATATGATCACCAT	TCCAAATCAGACAGCATCTTCTTATTTAGAGACGCCCAAGC	1743
Db	1435	TATATGATCACCATCAC	CAATCAGACAGCATCTTCTTATTTAGAGACGCCCAAGC	1494
Qy	1744	AGATGGCCAGCAAT	GAAGTTTCGGAAGAGGCTCAGGACACCCCTGCCTATGCGAAGTTGAA	1803
Db	1495	AGATGGCCCTGGAT	GAAGTTTAGAAGAGGCTCTGGACATCCTGCCTATGCTGAAGTTGAA	1554
Qy	1804	CCAGTTGGAGAAAG	AAGGTTTTTATTTGATTCAGAGCAGTGTCTAAAAATTT- TAGGACAGA	1862
Db	1555	CCAGTTGGAGAAAG	AAGGCTTTATTTGATTCAGAGCAGTGTCTAAAAATTTCTTAGGACAGA	1614

QY	1863	GCAGCACAGTACTGGCTTACAGGTGTTAAGACATAAAACCTTTGCTTATGATTTAAGACA	1922
DB	1615	AAACACACAGTACTGGCTTACAGGTGTTAAGACATAAAATTTTGCTATACCTTTAAGACA	1674
QY	1923	AAACAGACACAAACCCACACACACAAAGGAGCCCTAAACCTGCTGTAGACAGAAAGG	1982
DB	1675	AAACAAACAACA-----CACACACAACAACAGCTCTAGCTTCCTAGCTGAA- GA	1724
QY	1983	CGACGAGATTCTGGACAAGCCAGCCAGG-----AACATTGAAAGGAAACCTCAGACT	2037
DB	1725	AGACAAGATTCTGGACAAGCTCAGCCAGGAAACAAAGGGTAAACAAACAACTAAAACT	1784
QY	2038	TGTACAGACACCAATGTACAAATGATTAAAGNATTCCTAGTGGATGACATCCATGCTTC	2097
DB	1785	TATCAAGATACCAATTACACTGAACATAGAAATTCCTAGTGGAAATGTCATCTATAGTTC	1844
QY	2098	ACAAGGAACATCTCCGGTGGACTTGCACGAGAGTGTGACGAGATGACGATGCTTTGGTTT	2157
DB	1845	ACTCGAACATCTCCGGGACTTATCTGAGATATGACAAGATTATAATGCTTTTGGCTT	1904
QY	2158	AGGTGCAGGTTGCAAA	2174
DB	1905	AGGTGCAGGTTGCAAA	1921
RESULT 8			
AAAC87054			
ID	AAAC87054	standard; cDNA; 2557 BP.	
XX	AC	AAAC87054;	
XX	DT	20-APR-2001 (first entry)	
XX	DE	Nucleotide sequence of human polypeptide PRO6003.	
XX	KW	Human; secreted protein; transmembrane protein: PRO196; PRO444; PRO183;	
KW	KW	PRO185; PRO210; PRO215; PRO217; PRO242; PRO288; PRO365; PRO1361; PRO1308;	
KW	KW	PRO1183; PRO1272; PRO1419; PRO4999; PRO7170; PRO248; PRO353; PRO1318;	
KW	KW	PRO1600; PRO3940; PRO533; PRO301; PRO187; PRO337; PRO1411; PRO4356;	
KW	KW	PRO246; PRO265; PRO941; PRO10096; PRO6003; PRO6004; PRO350; PRO2630;	
KW	KW	PRO6309; cell death; genetic disorder; transgenic animal; gene therapy;	
XX	XX	ss.	
OS	Homo sapiens.		
XX	Key	Location/Qualifiers	
FH	CDS	601..2190	
FT	FT	/*tag= a	
XX	PN	WO200077037-A2.	
XX	XX	21-DEC-2000.	
XX	XX	22-MAY-2000; 2000WO-US14042.	
PF	XX	15-JUN-1999; 99US-0139695.	
PR	PR	20-JUL-1999; 99US-0145070.	
PR	PR	26-JUL-1999; 99US-0145698.	
PR	PR	17-AUG-1999; 99US-0149396.	
PR	PR	08-SEP-1999; 99WO-US20111.	
PR	PR	01-SEP-1999; 99WO-US20594.	
PR	PR	15-SEP-1999; 99WO-US21090.	
PR	PR	15-SEP-1999; 99WO-US21547.	
PR	PR	30-NOV-1999; 99WO-US28313.	
PR	PR	01-DEC-1999; 99WO-US28301.	
PR	PR	02-DEC-1999; 99WO-US28565.	
PR	PR	07-DEC-1999; 99US-0169495.	
PR	PR	05-JAN-2000; 2000WO-US00219.	
PR	PR	18-FEB-2000; 2000WO-US04341.	
PR	PR	22-FEB-2000; 2000WO-US04342.	
PR	PR	18-FEB-2000; 2000WO-US04414.	
PR	PR	02-MAR-2000; 2000WO-US05601.	
PR	PR	01-MAR-2000; 2000WO-US05841.	

20-MAR-2000; 2000WO-US07377.
30-MAR-2000; 2000WO-US08439.
15-MAY-2000; 2000WO-US13358.
17-MAY-2000; 2000WO-US13705.
(GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL,
PI Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Kijavini IJ, Mather JP, Napier MA, Pan J;
PI Pironi NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
PI Wood WI, Zhang Z;
XX WPI; 2001-050091/06.
DR P-PSDB; AAB31211.
XX
PT Isolated nucleic acid molecule encoding a PRO polypeptide which is a
PT transmembrane polypeptide is useful for gene therapy and identification
PT of related polypeptides -
XX
PS Claim 2; Fig 65; 244pp; English.
XX
CC The present sequence encodes a human secreted and transmembrane
CC polypeptide. The specification describes human polypeptides, designated
CC PRO196, PRO444, PRO183, PRO185, PRO210, PRO215, PRO217, PRO242, PRO286,
CC PRO365, PRO1361, PRO1308, PRO1183, PRO1272, PRO1419, PRO4999, PRO1170,
CC PRO248, PRO1318, PRO1600, PRO9940, PRO533, PRO301, PRO187,
CC PRO337, PRO1411, PRO3356, PRO2465, PRO941, PRO10096, PRO6003,
CC PRO6004, PRO350, PRO2630 and PRO6309. The biological activity of cells
CC can be modulated with agents that bind to these polypeptides, resulting
CC in the death of the cells. The polynucleotides encoding these
CC polypeptides are useful in the recombinant production of the
CC polypeptides, as a hybridisation probe to screen libraries to isolate
CC homologous sequences, or to map the gene. They may also be used for
CC analysing genetic disorders, and to produce transgenic animals which are
CC useful for the development and screening of therapeutically useful
CC reagents. The polynucleotides can also be used in gene therapy e.g. to
CC replace a defective gene.
XX
XX Sequence 2557 BP; 718 A; 639 C; 615 G; 585 T; 0 other;
XX
Query Match 65.4%; Score 1423.4; DB 22; Length 2557;
Best Local Similarity 85.2%; Pred. No. 0;
Matches 1662; Conservative 0; Mismatches 264; Indels 25; Gaps 6;
QY 233 GGGAGAGAGTCCGCGCAGCGCATGGCAAGTTCGCGGAGGCCGACCTGCCCGCAG 292
DB 578 GGGAGCGCCCGACCGCGGAAATGGCGAGGTTCGCGAGGCCGACCTGCCCGTGCAG 637
QY 293 GAGTTATGTTACTTTGCTCACTTTTAAACAGACCGGTTCCAGTTCGCCCGCAGCGGAGCGTG 352
DB 638 GAGTTATGTTACTTTGCCACTTCTTCAAGGACCAAGTTTCAGTTCCGCGATGGAAACCG 697
QY 353 GACACCATACCAATGATTGGATTATGAAGTTACAAAGCGTTTCCAGTTCGCCCGCAGGAGG 412
DB 698 GAGACCAATTCCTTGATTGGCGAGTGGAGTTACTCAGCGCTTCCTCCACAGAGGAGG 757
QY 413 GGGTAGAAGTGGACTCTCAAGCATACAAACACAGGTGGAAAGAAATGTGACCTTTTA 472
DB 758 AGTGGAGTTGATTCAACCGGTACAGCCACAGGTGGAAAGAAATGTGACCTTTCA 817
QY 473 AGCGAGTAGACAAACAGACGACGATGGGCCAAGCGTCTCCAGAGTCCAAAGGGTTCA 532
DB 818 AGCGGCTAGACAGAACCGGAGCAAGCGTGGCGAAGACTCTCTGAGCCCAAGAGCTTCA 877
QY 533 CTGACCTGTTACTGGATGACGACAGGACAAATAACACCCAGATAGAGGACAGCGATC 592
DB 878 CAGACTGCTGCTGGATGATGGCGAGGACAAATAACACTCAGATCAGGAGGATACAGCC 937
QY 593 ACAATTACTACATTTCTCGGATATATGTTCCAGCGGATTTCTGCCAGCGGATCTGTGGG 652
DB 938 ACAATTACTATATCTCGAATATATGTTCCATCTGATTTCTGCCAGCGGATTTATGGG 997

QY 553 TTACATACACCAATGGAAAAAGAACAAAGTGAAGATTCACGGGATACATTTTCCAACTC 712
DB 998 TGAACATACACCAATGGAAAAAGATAAAGTGAAGATTCATGGRATATTTGCCAATCTC 1057
QY 713 ATCGCAAGCTGCAAGAGTGAATCTGCTCTCGATTTTCCATTTTATGCTCATTTTCTAA 772
DB 1058 ATCGCAAGCTGCAAGAGTGAATCTGCTCTCGATTTTCCATTTTATGCTCATTTCTAC 1117
QY 773 ATGAAGTCTACTGTGGCACTGGGGTTTCATATATACATGAGAGTGTATACATGATGC 832
DB 1118 GTGAATCTACTGTGGCACTGGGGTTTCATATACATGAGAGTGTATACATGATGC 1177
QY 833 TCACAGCTACACAGTATATAGTCTCTTAAATGGCAAAATTTGATCCCACTGTATCCAGAA 892
DB 1178 TACACGCCACAGTACATAGCAGCTTTAATGGCAAAATTTGATCCCACTGTATCCAGAA 1237
QY 893 ATTCAACTCTCAGATATATTTGATATGACAGCTCTCTTGTGTCAGTGGGAGCATGTC 952
DB 1238 ATTCAACTCTCAGATATATTTGATATGACAGCTCTCTTGTGTCAGTGGGAGCATGTC 1297
QY 953 ACCTGAGGATATTTACAACTGGGAAGCTTCACATTTCCAGGCCACACTCTCTATGAGC 1012
DB 1298 ATCTCCAGATATATATAACCTGGGAGCTTCACATTTCCAGGCCACCTGCTCATGATG 1357
QY 1013 GCGCATCATCTTTGGATACAAAGAAATCCCTGCTTGTGTCACACAGATATAGTTCTACA 1072
DB 1358 GACGAATCATCTTTGGATACAAAGAAATCCCTGCTTGTGTCACACAGATATAGTTCTACA 1417
QY 1073 ACCATCCAGTGAAGTGGGTTGCTGATGATGCTGCTGTTGTCACAGGATCCAGCAAA 1132
DB 1418 ATCATCCAGTGAAGTGGGACTGTCGATGATGCTGCTGTTGTCACAGGATCCAGCAAA 1477
QY 1133 TACCAATCTTGAAGAGAAACAAATTTATGATATACCGAGTAGAATACAAATGTCCA 1192
DB 1478 TTCCCAATCTTGAAGAGAAACAAATTTATGATATACCGAGTAGAATACAAATGTCCA 1537
QY 1193 AAATTACCAACATCTCAGCTGTTGGAGATGACATCCACTTCCACATGCTCTCCAGTTCA 1252
DB 1538 AAATTACCAACATCTCAGCTGTTGGAGATGACATCCACTTCCACATGCTCTCCAGTTCA 1597
QY 1253 GTGTGGCCCTTGTGTCCTCGCATGTTGTTCACTGCACTGTTGTTGTCACAACTTC 1312
DB 1598 GATGTGGCCCTTGTGTCCTCGCATGTTGTTCACTGCACTGTTGTTGTTGTTGTTGTTGTT 1657
QY 1313 AAAGATGCTCCAGTGGATTTGATCGCCATCGCAGAGTGGTGGAGAGTGGATGGATGG 1372
DB 1658 AAAGATGCTCCAGTGGATTTGATCGCCATCGCAGAGTGGTGGAGAGTGGATGGATGG 1717
QY 1373 AAGAGTACAGTCAAAAGAGAAAGATGTGTGAGAGACAGAGCCAGGAGAGA ---CATCTC 1429
DB 1718 AAG-----AGTCAAAAGAGAAAGATGTGTGAGAGATACAGAACAGTGGAACTTCTTCTC 1771
QY 1430 AACTACACAGACCTCCACAGCACCACCATGCAATTCAGGGTCTGACCCACCCAGGA 1489
DB 1772 GAACCCACCAACCGTAGGAGCGCAACCCAGTTCAGGGTCTGTAACCTACCCAGAA 1831
QY 1490 GAGCTGTGATCTCTCAGATGCTTACAGCTGCCCTGACAGAGATGACACAGAGATAGCC 1549
DB 1832 GAGCAGTACTTCTCAGTTTCCACAGCCCTCCCTTACAGAGATGATACCAAGATAGC 1891
QY 1550 TACATCTCAAGAGAGTGGAGCTCCACAGATGACAGTGCAGCTGAGAGAGAGAGAGAA 1609
DB 1892 TACATCTCAAGAGATGAGAGCTTCTACAGATGACAGTGCAGCTGAGAGAGAGAGAGAA 1951
QY 1610 CCTCCATCAGCGCTCATTTGTTGGAATTTCTATCTTCTCTCTCTCTCTCTCTCTCTCTCT 1669
DB 1952 CCTCCATCAGCGCTCATTTGTTGGAATTTCTATCTTCTCTCTCTCTCTCTCTCTCTCT 2011
QY 1670 TTCTGTGACAGTGTATATGATACCACTCCAACTACAGCAGCAGCATCTTCTTCTATTG 1729
DB 2012 TTCTGTGACAGTGTATATGATACCACTCCAACTACAGCAGCAGCATCTTCTTCTATTG 2071
QY 1730 AGNAGCGCCACAGAGATGGCCAGCAATGAAGTTTCGAGAGGCTCAGGACACCCCTGCT 1789

```

Db 2072 AGAGACGCCAAGCAGAGTGGCTGGATGAAGTTAGAGAGGCTCTGGACATCTGGCT 2131
QY 1790 ATGCAGAGTTGAACACAGTTGGAGAGAGAGAGTTTATTTATTCAGAGAGTGTCTAAA 1849
Db 2132 ATGCTGAAGTTGAACACAGTTGGAGAGAGAGAGGCTTTATTTATTCAGAGAGTGTCTAAA 2191
QY 1850 ATTT-TAGGACAGAGCAGCAGCAGTACTGCTTTACAGGTGTTAAGACTAAACTTTTGCTT 1908
Db 2192 ATTTCTAGGACAGCAGCAGCAGTACTGCTTTACAGGTGTTAAGACTAAACTTTTGCTT 2251
QY 1909 ATGCATTTAGACAAACAGACACACACACACACACACACACACACACACACACACACACAC 1968
Db 2252 ATACCTTTAAGACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAAC 2302
QY 1969 TGTAGACAGAGGCGGACGAGTCTTCGGACAGCCAGCCAGG-----AACATTGAAA 2023
Db 2303 TGTAGCCTGAA-GAAGACAGATTCTUGGACAGCTCAGCCAGGAAACAAAGGGTAAAC 2361
QY 2024 GGAACACTCAGACTGTACAGACACACACACACACACACACACACACACACACACACACAC 2083
Db 2362 AAAAACTAAACTTATACAGATACCATTTACACTGAACATAGAAATTCCTTAGTGGAT 2421
QY 2084 GACATCATGTTTACACAGGAACATCTCCGTTGGACTTGCAGGAGTGTGACGAGATGAC 2143
Db 2422 GTATCTATAGTTCACTCGGAACATCTCCGTTGGACTTATCTGAATATGACAAAGTTAT 2481
QY 2144 GATGCTTTTGTAGTGCAGGTTGCAAA 2174
Db 2482 AATGCTTTTGTAGTGCAGGTTGCAAA 2512

```

RESULT 9

```

AAH23067
ID AAH23067 standard; cDNA; 1590 BP.
XX AC
XX AAH23067;
XX DT
XX 17-SEP-2001 (first entry)
XX DE Stem cell growth factor-like polypeptide coding sequence.
XX KW Stem cell growth factor-like polypeptide; leukemia; hemophilia; human;
KW degenerative disease; Alzheimer's disease; nutritional supplement;
KW cytotatic; nontropic; neuroprotective; hemostatic; antisense-therapy;
KW gene-therapy; cell proliferation; stem cell growth factor; ss.
XX OS Homo sapiens.
XX FH
XX Key Location/Qualifiers
XX CDS 1..1590
XX /*tag= a
XX WO200153500-A1.
XX PD 26-JUL-2001.
XX PF 23-DEC-2000; 2000WO-US35260.
XX PR 21-JAN-2000; 2000US-0488725.
XX PR 07-APR-2000; 2000US-0545714.
XX PR 11-APR-2000; 2000US-0547358.
XX XX (HYSE-) HYSEQ INC.
XX PA Labat I, Tang YF, Drmanac RT, Liu C, Lee J, Mize NK, Childs J;
XX PI Chao C;
XX DR WPI: 2001-451909/48.
XX DR P-PSDB; AAB85394.
XX PT Isolated polypeptide with stem cell growth factor-like activity for
XX treatment of leukemia, hemophilia, and degenerative diseases like
PT

```

```

PT Alzheimer's disease and to generate new tissues and organs -
XX Claim 1; Page 140-141; 154pp; English.
XX

```

The invention provides novel human stem cell growth factor-like polypeptides and polynucleotides encoding them. The polypeptides having stem cell growth factor-like activity, can be expressed by standard recombinant methodology. The polynucleotides and polypeptides can be used to induce differentiation of embryonic and adult stem cells to give rise to different cell types. They may also be used in the treatment of leukemia, hemophilia, and degenerative diseases like Alzheimer's disease. They may also be utilized to generate new tissues and organs that may aid patients in need of transplants. They can also be used as nutritional supplements. The present sequence represents a stem cell growth factor-like polypeptide coding sequence.

Sequence 1590 BP; 467 A; 382 C; 364 G; 377 T; 0 other;

Query Match 56.9%; Score 1238; DB 22; Length 1590;

Best Local Similarity 86.9%; Pred. No. 0;

Matches 1387; Conservative 0; Mismatches 200; Indels 9; Gaps 2;

QY 256 ATGCAAGGTTCCGGAGGGCGGACCTGGCGCAGCAGGAGTTATGTTACTTTGTCTACTTT 315

Db 1 ATGCGGAGGTTCCCGAAGCGCGACCTGGCGCTGCAGGAGTTATGTTACTTTGCCACTTC 60

QY 316 TTAACAGACCGGTTCCAGTTCCGCCACGAGGAGCCCTGGACACCATACCAATGATTTGGAT 375

Db 61 TTCACGGACCAAGTTTCAGTTCCGCCGATGGGAAACCGCGAGACCAATCTTGTATTGGCAG 120

QY 376 TATGAAGTTTAAACAGCTTTTCTTGGATGAAGAGGGGTAGAGTGTCTCTCAAGCA 435

Db 121 TATGGAGTTACTCAGGCTTCCCTCACAGAGAGGAGGTGGAAGTTGATTCACACGG 180

QY 436 TACAACACAGGTTGGAAGAAATGTGGACCTTTTAAGSCAGTAGACACAAACAGAGCC 495

Db 181 TACAGCCACAGGTTGGAAGAAACTTGGACTTTCTCAAGCGGTAGACACGACCGAGCA 240

QY 496 AGCATGGCCCAAGCTCTCCAGAGTCCAAAGGTTCTACTGACCTGTACTTGGATGACGA 555

Db 241 AGCTGCGCCAGACTCTCTGAGCCGAGAGGTTTACAGACCTGTCTGTTGATGATGG 300

QY 556 CAGGACAATACACCCAGATAGAGAGGACACCGGATACAAATTTACTACATTTCTCGGATA 615

Db 301 CAGGACAATACACTCAGATCGAGAGGAGATACAGACCAATTTACTATATATCTCGAATA 360

QY 616 TATGTCACCGGATTTCTGCCCGGGATCTGGGTTAAACATAGACCAATGGAATAA 675

Db 361 TATGTCATCTGATTTCTGCCCGGGATTTATGGTGAACATAGACCAATGGAATAA 420

QY 676 GACAAAGTGAAGATTCACGGGATACCTTCCAACTCATCGGCAAGCTGCAAGAGTGAAT 735

Db 421 GATAAGTGAAGATTCATGGAATATTTCCAACTCATCGGCAAGCTGCAAGAGTGAAT 480

QY 736 CTGTCCTTCGATTTTCCATTTTATGGTCAATTTCTAAATGAAGTCACTGTGGCAACTGG 795

Db 481 CTGTCCTTCGATTTTCCATTTTATGGCCACTTCTCTAGTGAATCACTGTGGCAACTGG 540

QY 796 GGTTCATATATACCTGGAGAGTTGTACATCGAATGCTCACAGCTACACAGTATATAGCT 855

Db 541 GGTTCATATACACTCGGAGAGTGTACATCGAATGCTAACACCCACACAGTATATAGCA 600

QY 856 CCTTAATGCGAAATTTGATCCAGTGTATCCAGAAATTCACATGTCAGATTTTTGAT 915

Db 601 CCTTAATGCGAAATTTGATCCAGTGTATCCAGAAATTCACATGTCAGATTTTTGAT 660

QY 916 AATGCGCAGCTCTGTTGTCCAGTGGGACCATGTCCACCTCGAGGATTAATTAACACCTG 975

Db 661 AATGCGCAGCTCTGTTGTCCAGTGGGACCATGTACATCTCCAGGATTAATTAACCTG 720

QY 976 GGAAGCTTCATTCACAGGCGCAACTCTCTCATGACGGGCGCATCATCTTTGGATCAAA 1035

Db 721 GGAAGCTTCATTCACAGGCGCAACCTCTCATGATGGACGAATCATCTTTGGATCAAA 780

QY	1036	GAATCCCTGCTCTGGTGCACAGATAAGTTCTACCAACCATCCAGTGAAGTCGGGTG	1095
DB	781	GAATTCCTGCTCTGGTGCACAGATAAGTTCAACCAATCATCCAGTGAAGTCGACTG	840
QY	1096	TCTGATGCATTTCTCGTGGTCCACAGATCCAGCAAAATACCAATGTTCCGAAGAACA	1155
DB	841	TCCGATGCATTTCTGGTTGTCACAGATCCACAAATCCCAATGTTCCGAAGAACA	900
QY	1156	ATTTATGAATATACCCGAGTAGAAGTTACAAATGTCCTCAAAATACCAACATCTCAGCTGTG	1215
DB	901	ATTTATGAATACCAACCGAGTAGAGCTTACAAATGTCAAAATACCAACATTCGGGTGTG	960
QY	1216	GAGATGACTCCACTTCCACATGTCCTCAGTTCATGTGTGGCCCTCTGTGTGCTCTCG	1275
DB	961	GAGATGACCCCATATACCCACATGCTCCAGTTTACAGATGTGGCCCTGTGTATCTCT	1020
QY	1276	CAGATTGGTTTCAACTGCAGTTGGTGACAACTTCAAGATGCTCCAGTGGATTTGAT	1335
DB	1021	CAGATTGGTTCACCTGCAGTTGGTGTAGTAACTTCAAGATGTTCCAGTGGATTTGAT	1080
QY	1336	CGCCATCGGCAGACTGGGTGGACAGTGGATGCCCGGAAGAGGTACAGTCAAAAGAGAAG	1395
DB	1081	CGTCATCGGCAGACTGGGTGGACAGTGGATGCCCTGAAG-----AGTCAAAAGAGAAG	1134
QY	1396	ATGTGTGAGAAGACAGAGCCAGCAGAGAGA---CATCTCAAACACTACCAAGACCTCCACACG	1452
DB	1135	ATGTGTGAGAATACAGAACACAGTGGAACTTCTTCTCGAACCCACCAACATAGGAGCG	1194
QY	1453	ACCACATGCAATTCAGGTCCTGACCCACCACGAGAGAGTGTGCATCTCAGATGCGCT	1512
DB	1195	ACAACCAACCCAGTTCAGGTCCTTACTACCCACGAAGAGCAGTGACTTCTCAGTTTCC	1254
QY	1513	ACCAGCTGCGCTACAGAAATGACAGAAATAGCGCTACATCTCAAAGACAGTGGAGCC	1572
DB	1255	ACCAGCTCCCTACAGAAGATGATACCAAGATAGCACTACATCTAAAGATATGGAGCT	1314
QY	1573	TCCACAGATGACAGTGCAGCTGAGAAGAAGGAGAACCTCCATGCAGGCCCTCATTTGT	1632
DB	1315	TCTACAGATGACAGTGCAGCTGAGAAGAAGGGGAGACCTCCACGCTGGCCTCATGTT	1374
QY	1633	GGAAATTCATCTTGGTCTCATTTATAGCAGGGGCCATTCGTGTGACAGTGTATATGTAT	1692
DB	1375	GGAAATCTCATCTTGGTCTCATTTATAGCCACAGCCATTCCTGTGACAGTCTATATGTAT	1434
QY	1693	CACATCCACATACGAGCCAGCATCTTCTTTCATTGAGAGAGCCGCCAAGCAGATGGCCA	1752
DB	1435	CACCACCCCAATACGAGCCAGCATCTTCTTTATTGAGACAGCCCAAGCAGATGGCCT	1494
QY	1753	GCAATGAAGTTTTCGAGAGGCTCAGGACACCTGCTATGCAGAAGTTGAACCAAGTTGGA	1812
DB	1495	CGATGATGAGTTAGAGAGGCTCTGGACATCTGCTATGCTGAAGTTGAACCAAGTTGGA	1554
QY	1813	GAGAAAGAAGTTTATTGTPATCAGAGCAGTGTCTAA	1848
DB	1555	GAGAAAGAAGCTTTATTGTPATCAGAGCAGTGTCTAA	1590

RESULT 10
AA T60009/C

AA160009/C
ID AA160009 standard: cDNA: 2668 bp.

XX
XX

AC AAI60009;

XX
XX
XXXXX

DT 22-OCT-2001 (first entry)

XX
XX

DE Human polynucleotide SEQ ID NO 3998.

XX
XX
KW Human; neoplastic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Sny-Prager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW

leukaemia; ss.
Homo sapiens.
WO200153312-A1.
26-JUL-2001.
26-DEC-2000; 2000WO-US34263.
21-JAN-2000; 2000US-0488725.
25-APR-2000; 2000US-0522317.
09-JUL-2000; 2000US-0598042.
19-JUL-2000; 2000US-0620312.
03-AUG-2000; 2000US-0653450.
14-SEP-2000; 2000US-0662191.
19-OCT-2000; 2000US-0693036.
29-NOV-2000; 2000US-0727344.
(HYSE-) HYSEQ INC.
Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
Zhao QA, Zhou P, Goodrich R, Drmanac RT;
WPI; 2001-442253/47.
P-PSDB; AAM40853.
Novel nucleic acids and polypeptides, useful for treating disorders
such as central nervous system injuries -
Claim 1; SEQ ID NO 3998; 10078pp; English.
The invention relates to human nucleic acids (AAI57798-AAI61369), and
the encoded polypeptides (AAM38642-AAM42213) with nootropic,
immunosuppressant and cytostatic activity. The polynucleotides are useful
in gene therapy. A composition containing a polypeptide or polynucleotide
of the invention may be used to treat diseases of the peripheral nervous
system, such as peripheral nervous injuries, peripheral neuropathy and
localised neuropathies and central nervous system diseases, such as
Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
utilisation of the activities such as: Immune system suppression,
activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
and thrombolytic activity, cancer diagnosis and therapy, drug screening,
assays for receptor activity, arthritis and inflammation, leukaemias and
C.N.S disorders.
Note: The sequence data for this patent did not form part of the printed
specification.

Query Match 54.98; Score 1195.2; DB 22; Length 2668;
Best Local Similarity 87.08; Pred. No. 0;
Matches 1390; Conservative 0; Mismatches 183; Indels 25; Gaps 6;

QY	586	ACGGATCACAAATTACTACATTTCTCGGATATATGGTCCAGCGGATTTGCCAGCGGGAT	645
Db	2643	ACAGACCACAATTACTATATATCTCGAATATATGGTCCATCTGATCTTGCCAGCGGGAT	2584
QY	646	CTGTGGGTTAACATAGACCAAAATGGGAAAAGACAAGTGAAGATTCACGGGATATTTC	705
Db	2583	TTATGGGTGAACATAGACCAAAATGGGAAAAGATAAAGTGAAGATTCATGGAATATTGTCC	2524
QY	706	TAACACTATCGGCAAGCTGCAAGAGTGAATCTGTCTCTCGAATTTTCCATTTTATGGTCAT	765
Db	2523	AATACTATCGGCAAGCTGCAAGAGTGAATCTGTCTCTCGAATTTTCCATTTTATGGCCAC	2464
QY	766	TTTCTAAATGAAGTCACCTGTGGCACTGGGGTTTCATATATCTACTGGAGAGTTGTACAT	825
Db	2463	TTCTTACGTGAAATCACTGTGGCAACCGGGGTTTCATATACACTGGAGAGTGTGTACAT	2404
QY	826	CGAATGCTCAGCTACACAGTATATAGCTTCCTTTTAATGGCAAAATTTTGATCCCGCAGTGA	885

QY 1723 TTCATTGAGAGAGCCCAAGCAGAGATGGCCAGCAATGAATTTCCAGAGGCTCAGGACAC 1782
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1160 TTATTGAGAGAGCCCAAGCAGAGATGGCTCGATGAAGTTTAGAAGAGGCTCTGGACAT 1219
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1783 CCGCTATGTCAGAGCTTGAACCACTGGAGAGAAAGAGTTTATTGTATCAGAGCAG 1842
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1220 CCGCTATGTCAGAGCTTGAACCACTGGAGAGAAAGAGCTTATTGTATCAGAGCAG 1279
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1843 TGTCTAAATTT-TAGACAGACAGACAGCAGTACTGGCTTACAGGTGTTAGACTAAAC 1901
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1280 TGTCTAAATTTCTAGACAGACAGACAGCAGTACTGGCTTACAGGTGTTAGACTAAAT 1339
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1902 TTTGCTTATGCTTTTAAAGCAACACAGACACACACCCCAACACACCAAGAGCCCT 1961
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1340 TTGCTCTATACCTTTAAGCAACACCAACCAACA-----CACACACCAACAGCTCT 1390
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1962 AAATGCTGTAGACAGAGGGCGAGAGATTTCTGGACAAGCCCAAGCCAG-----AAC 2016
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1391 AAGCTGCTGTAGCTGAA--GAAGACAAGATTTCTGGACAAGCTCAGCCAGGAACAAG 1449
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 2017 ATTGAAGGAACACTCAGACTTGTACAGACACCACTGTACCAATGATTAAAGATTCCTTA 2076
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1450 GGTAAACAAACTTAAACTTATCAAGATACCATTACACTGAACATAGATTTCCCTA 1509
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 2077 GTGGAATGACATCCATGGTTCAAGAGACATCTCCGGTGGACTTGGCCAGGAGTGTGACG 2136
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1510 GTGGAATGCTCTATAGTCTACTCGGAACATCTCCCGTGGACTTATCTGAAGTATGACA 1569
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 2137 AGATGACGATGCTTTTGGTTTAGTGTGACGGGTTGCAAA 2174
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1570 AGATTATATGCTTTGGCTTAGTGTGACGGGTTGCAAA 1607

RESULT 14
 AAH23064
 ID AAH23064 standard; cDNA; 2668 BP.
 XX
 AC AAH23064;
 XX
 DT 17-SEP-2001 (first entry)
 XX
 DE Stem cell growth factor-like polypeptide encoding cDNA.
 XX
 KW Stem cell growth factor-like polypeptide; leukemia; hemophilia; human;
 KW degenerative disease; Alzheimer's disease; nutritional supplement;
 KW cytosolic; nootropic; neuroprotective; hemostatic; antitense-therapy;
 KW gene-therapy; cell proliferation; stem cell growth factor; ss.
 XX
 OS Homo sapiens.
 XX
 EH Key Location/Qualifiers
 FT CDS 107..1285
 FT /*tag= a
 XX
 PN WO200153500-A1.
 XX
 PD 26-JUL-2001.
 XX
 EF 23-DEC-2000; 2000WO-US35260.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 07-APR-2000; 2000US-0545714.
 PR 11-APR-2000; 2000US-0547358.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Labat I, Tang YT, Drmanac RT, Liu C, Lee J, Mize NK, Childs J;
 PI Chao C;
 XX
 DR WPI: 2001-451909/48.
 DR P-PSDB; AAB85393.

PT Isolated polypeptide with stem cell growth factor-like activity for
 PT treatment of leukemia, hemophilia, and degenerative diseases like
 XX Alzheimer's disease and to generate new tissues and organs -
 PS Claim 1; Page 129-131; 154pp; English.
 XX
 CC The invention provides novel human stem cell growth factor-like
 CC polypeptides and polynucleotides encoding them. The polypeptides having
 CC stem cell growth factor-like activity, can be expressed by standard
 CC recombinant methodology. The polynucleotides and polypeptides can be
 CC used to induce differentiation of embryonic and adult stem cells to give
 CC rise to different cell types. They may also be used in the treatment of
 CC leukemia, hemophilia, and degenerative diseases like Alzheimer's disease.
 CC They may also be utilized to generate new tissues and organs that may aid
 CC patients in need of transplants. They can also be used as nutritional
 CC supplements. The present sequence represents a stem cell growth factor-
 CC like polypeptide encoding cDNA.
 XX
 SQ Sequence 2668 BP; 851 A; 579 C; 517 G; 721 T; 0 other;
 Query Match 54.9%; Score 1195.2; DB 22; Length 2668;
 Best Local Similarity 87.0%; Pred. No. 0;
 Matches 1390; Conservative 0; Mismatches 183; Indels 25; Gaps 6;
 QY 586 ACGGATCACAATTACTACATTTCTCGGATATATGTCAGCGGATTCGCCAGCGGGAT 645
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 26 ACAGACCACAATTACTATATATCGAATATATGTCCTCATCTGTCCTGCCAGCGGAT 85
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 646 CTGTGGTTTAAACATAGACCAACCAATGGAAGAAACAAAGTGAAGATTACGGGATCTTCC 705
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 86 TTAAGGTGAACATAGACCAACCAATGGAAGAAATGAAGTGAAGATTCTGATATGTC 145
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 706 AACACTCATCGGCAAGCTCAAGAGTGAATCTGCTTCGATTTTCCATTTTATGGTCA 765
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 146 AATACTCATCGGCAAGCTCAAGAGTGAATCTGCTTCGATTTTCCATTTTATGGCCAC 205
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 766 TTCTTAAATGAAGTCACTGTGCAACTGGGGTTCATATATACCTGAGAGATTCTACAT 825
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 206 TTCTAGTGAATCACTGTGCAACCGGGTTCATATATACCTGGAGAGTCTGATAT 265
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 826 CGAATGCTCACAGCTACACAGTATATAGCTTCCTTAATGGCAAAATTTGATCCCCAGTGA 885
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 266 CGAATGCTAACAGCCACACAGTACATAGCACCTTAAATGGCAAAATTTGATCCCCAGTGA 325
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 886 TCAGAAATTCRACTCTCAGATATTTGATATGACAGAGCTCTTGTGTCAGAGTGGAC 945
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 326 TCAGAAATTCRACTCTCAGATATTTGATATGACAGAGCTCTTGTGTCAGAGTGGAC 385
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 946 CATGTCCACCTGCAGGATAATTACACCTGGGAAGCTTCACATTCAGGCCACACTCCTC 1005
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 386 CATGTACATCTCCAGGATTAATTATACCTGGGAAGCTTCACATTCAGGCCACACTCCTC 445
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1006 ATGGAGGGGCGCATCATCTTGGATACAAAGAAATCCCTGCTCTGTCACAGATAGT 1065
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 446 ATGGATGGAGGAATCATCTTGGATACAAAGAAATTCCTGCTCTGTCACAGATAGT 505
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1066 TCTACCAACCATCCAGTGAAGTCGGGTGCTCTGATGCAATTTGTCGTCACAGGATC 1125
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 506 TCAACCAATCATCCAGTGAAGTCGGAGTCCGATGCAATTTGTCGTCACAGGATC 565
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1126 CAGCAATATCCCAATGTCGAGAGAAACAATTTATGAATATCAGGAGTAGAATACAA 1185
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 566 CAACAAATTTCCCAATGTCGAGAGAAACAATTTATGAATACACAGTAGAGTAGACAA 625
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1186 ATGTCCAAATTTACCAACATCTCAGCTGTGGAGATGACTCCACTTCCACATGTCCTCAG 1245
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 526 ATGTCAAAATTTACCAACATTTCCGGTGTGGAGATGACCCCATTTACCCACATGCCCTCAG 685
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1246 TTCAATGTTGTGGCCCTGTGTGCTTCGAGATGTTGTTTCACTGCAAGTGTGGTGACG 1305
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 686 TTAAACAGATGTGGCCCTGTGTATCTTCTCAGATTTGGCTTCAACTGCAGTTGGTGTAGT 745
 QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1306 AAACCTTCAAGATGCTCCAGTGGATTTGATCGGCATCGGAGGACTGGGTGGACAGTGA 1365

|||||
746 AAATCTCAAGATGTTCCAGTGGATTTGATCGTCATCGCGAGGACTGGTGGACAGTGA 805
1366 TGCCGGAAGAGGTACAGTCAAAAGAGAGATGTGTGAGAGACAGAGACCCAGGAGAGACA 1425
806 TGCCCTGAG-----AGTCAAGAGAGAGATGTGTGAGATACAGACACCACTGGAAC 859
1426 ---TCTCAACTACACAGACCTCCACAGGACCCACCATGCAATTCAGGGTCTGACCAAC 1482
860 TCTTCTCGAACCAACCAACCATAGGAGCGGACCAACCCAGTTCAGGGTCTCAACTACC 919
1483 ACCAGGAGAGCTGTGACATCTCAGATGCTTACAGCTCGCTTACAGAGATGACACCAAG 1542
920 ACCAGAGAGAGTGTGATCTCAGTTCAGTTCACAGCTCCCTTACAGAGATGATACCAAG 979
1543 ATAGCCCTACATCTCAAGAGAGTGGAGCTCCACAGATGACAGTGCAGTGCAGAGAGAA 1602
980 ATAGCATACATCAAAAGATATGAGCTTACAGATGACAGTGCAGTGCAGAGAGAA 1039
1603 GGAGGACCTCCATGACGAGCTCATGTGTGAATCTCATCTTGGTCTCTCATATAGCA 1662
1040 GGGGAACCTCCACGCTGGCTCACTGTTGGAATCCCTCATCTGCTCTCATTTAGCC 1099
1663 GCGGCCATCTGTGACAGTGTATGATATACCATGATCCCAATCAGCAGCAGCATCTTC 1722
1100 ACAGCCATCTTGTGACAGTGTATGATATATGATATGATATGATATGATATGATATGAT 1159
1723 TTCAATGAGAGCGCCCAAGCAGATGCCAGCAATGAGTTCGAGAGGCTCAGGACAC 1782
1160 TTTATGAGAGCGCCCAAGCAGATGCCAGTGGCTGAGTGTAGAGAGGCTCTGGACAT 1219
1783 CCGTCCATGCAAGATGTAACAGTGGAGAGAAAGAGTGTATGATGATGATGATGATGAT 1842
1220 CCGTCCATGCTGAAGTGAACAGTGGAGAGAAAGAGTGTATGATGATGATGATGATGAT 1279
1843 TGCTAAATTT-TAGGACAGAGCGGACAGGATGCTGCTTACAGTGTAAAGACTAAAC 1901
1280 TGCTAAATTTTAGGACAGAGCAACAGCAGTACTGTTTACAGTGTAAAGACTAAAT 1339
1902 TTTGCTTATGATTTAGCAAAACAGACACACCAACCCCAACCAACCAACCAACCAACCA 1961
1340 TTTGCTTATGCTTTTAAAGCAAAACCAACCA-----CACACACAAACCAAGCTCT 1390
1962 AAATGCTGTAGACAGAGCGGACAGGATTTCTGACAGACCCAGCCAGG-----RAC 2016
1391 AAGTGTGTAGCTGTAA--GAAGACAGATTTCTGACAGGCTCAGCCAGGAAACAAAG 1449
2017 ATTGAAGGAAACTGACGCTGTACAAGACACCATGTACAATGATTAAGAAATCCCTTA 2076
1450 GGTAAACAAACTAAACTTATACAGATACCATTTACACTGACATAGATTCCTTA 1509
2077 GTGGAATGACATCATGTTTCAAGAGACATCTCCGTTGGACTTCCAGGAGTGTGAGG 2136
1510 GTGGAATGATCATATATGTTTCACTCGGACATCTCCGTTGGACTTATCTGAATATGACA 1569
2137 AGATGACATGCTTTTGTGTTTGTAGTGCAGGTTGCAAA 2174
1570 AGATTAAATGCTTTTGGCTTTAGTGTGAGGTTGCAAA 1607

RESULT 15
AA158223
ID AA158223 standard; cDNA; 2275 BP.
XX
AC AA158223;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 426.
KW Human; nontropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

anyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
leukaemia; ss.
Homo sapiens.
WO200153312-A1.
XX 26-JUL-2001.
XX 26-DEC-2000; 2000WO-US34263.
XX 21-JAN-2000; 2000US-0488725.
XX 25-APR-2000; 2000US-0552317.
XX 03-JUL-2000; 2000US-0598042.
XX 13-JUL-2000; 2000US-0620312.
XX 03-AUG-2000; 2000US-0653450.
XX 14-SEP-2000; 2000US-0662191.
XX 19-OCT-2000; 2000US-0693036.
XX 29-NOV-2000; 2000US-0727344.
(HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
XX Zhao QA, Zhou P, Goodrich R, Drmanac R;
XX WPI: 2001-442253/47.
XX P-PSDB: AAM39067.
XX Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX Claim 1; SEQ ID NO 426; 10078pp; English.
XX The invention relates to human nucleic acids (AA157798-AA161369) and
XX the encoded polypeptides (AAM38642-AA42213) with nontropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: Immune system suppression,
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemia and
XX C.N.S disorders.
XX Note: The sequence data for this patent did not form part of the printed
XX specification.
XX Sequence 2275 BP; 571 A; 596 C; 579 G; 529 T; 0 other;
Query Match 53.5%; Score 1165.2; DB 22; Length 2275;
Best Local Similarity 82.3%; Pred. No. 0;
Matches 1410; Conservative 0; Mismatches 273; Indels 31; Gaps 5;
QY 2 TTGTGCTCAGTGGGGCTGCGAGGCTGACAGTGTGACAGTGTGACAGTGTGACAGTGTG 61
DB 512 TTCAGTGTGCGGTGAGGGCTGCGAGTGTGCGAAGTGTGCAAGAGAGAGCTCAGAGTCCGA 571
QY 62 AGAGGGTTCAGCT-----GTCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 108
DB 572 AGAGCGCTGCGCTCTACTGCGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 631
QY 109 CCTAGCGAAGTGTGACAGGCTCCGAGTCCCAAGACTCACCAGAGCTCAGAGCTCGGCC 168
DB 632 CGCAGCGACATTTACAAAGGCTCCCGGTCCTA-CGAGAGCGATCCGAGCGTTGGCC 690
QY 169 GTGTCGCCCCATCCCGAGGATTAACCCCGAGCCCGAGGCTCTCAAGAAAAATTCGTGG 228
DB 691 CGGTGCGCCTATTGTCATCGGAGCCCGGAGCAGCCGG-----CGAAGGACTGGCGG 742

anyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
leukaemia; ss.
Homo sapiens.
WO200153312-A1.
XX 26-JUL-2001.
XX 26-DEC-2000; 2000WO-US34263.
XX 21-JAN-2000; 2000US-0488725.
XX 25-APR-2000; 2000US-0552317.
XX 03-JUL-2000; 2000US-0598042.
XX 13-JUL-2000; 2000US-0620312.
XX 03-AUG-2000; 2000US-0653450.
XX 14-SEP-2000; 2000US-0662191.
XX 19-OCT-2000; 2000US-0693036.
XX 29-NOV-2000; 2000US-0727344.
(HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
XX Zhao QA, Zhou P, Goodrich R, Drmanac R;
XX WPI: 2001-442253/47.
XX P-PSDB: AAM39067.
XX Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX Claim 1; SEQ ID NO 426; 10078pp; English.
XX The invention relates to human nucleic acids (AA157798-AA161369) and
XX the encoded polypeptides (AAM38642-AA42213) with nontropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: Immune system suppression,
XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemia and
XX C.N.S disorders.
XX Note: The sequence data for this patent did not form part of the printed
XX specification.
XX Sequence 2275 BP; 571 A; 596 C; 579 G; 529 T; 0 other;
Query Match 53.5%; Score 1165.2; DB 22; Length 2275;
Best Local Similarity 82.3%; Pred. No. 0;
Matches 1410; Conservative 0; Mismatches 273; Indels 31; Gaps 5;
QY 2 TTGTGCTCAGTGGGGCTGCGAGGCTGACAGTGTGACAGTGTGACAGTGTGACAGTGTG 61
DB 512 TTCAGTGTGCGGTGAGGGCTGCGAGTGTGCGAAGTGTGCAAGAGAGAGCTCAGAGTCCGA 571
QY 62 AGAGGGTTCAGCT-----GTCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 108
DB 572 AGAGCGCTGCGCTCTACTGCGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 631
QY 109 CCTAGCGAAGTGTGACAGGCTCCGAGTCCCAAGACTCACCAGAGCTCAGAGCTCGGCC 168
DB 632 CGCAGCGACATTTACAAAGGCTCCCGGTCCTA-CGAGAGCGATCCGAGCGTTGGCC 690
QY 169 GTGTCGCCCCATCCCGAGGATTAACCCCGAGCCCGAGGCTCTCAAGAAAAATTCGTGG 228
DB 691 CGGTGCGCCTATTGTCATCGGAGCCCGGAGCAGCCGG-----CGAAGGACTGGCGG 742

229	QY	GCAGGGGAGAGAGTTCGGCGCAGCGGATGGCAAGGTTCCGGAGGCGCCGACTGGCCGCA	288
230	QY		
231	QY		
232	QY		
233	QY		
234	QY		
235	QY		
236	QY		
237	QY		
238	QY		
239	QY		
240	QY		
241	QY		
242	QY		
243	QY		
244	QY		
245	QY		
246	QY		
247	QY		
248	QY		
249	QY		
250	QY		
251	QY		
252	QY		
253	QY		
254	QY		
255	QY		
256	QY		
257	QY		
258	QY		
259	QY		
260	QY		
261	QY		
262	QY		
263	QY		
264	QY		
265	QY		
266	QY		
267	QY		
268	QY		
269	QY		
270	QY		
271	QY		
272	QY		
273	QY		
274	QY		
275	QY		
276	QY		
277	QY		
278	QY		
279	QY		
280	QY		
281	QY		
282	QY		
283	QY		
284	QY		
285	QY		
286	QY		
287	QY		
288	QY		
289	QY		
290	QY		
291	QY		
292	QY		
293	QY		
294	QY		
295	QY		
296	QY		
297	QY		
298	QY		
299	QY		
300	QY		
301	QY		
302	QY		
303	QY		
304	QY		
305	QY		
306	QY		
307	QY		
308	QY		
309	QY		
310	QY		
311	QY		
312	QY		
313	QY		
314	QY		
315	QY		
316	QY		
317	QY		
318	QY		
319	QY		
320	QY		
321	QY		
322	QY		
323	QY		
324	QY		
325	QY		
326	QY		
327	QY		
328	QY		
329	QY		
330	QY		
331	QY		
332	QY		
333	QY		
334	QY		
335	QY		
336	QY		
337	QY		
338	QY		
339	QY		
340	QY		
341	QY		
342	QY		
343	QY		
344	QY		
345	QY		
346	QY		
347	QY		
348	QY		
349	QY		
350	QY		
351	QY		
352	QY		
353	QY		
354	QY		
355	QY	</	

Search completed: June 23, 2003, 19:45:44
Job time : 494 secs